Tumor suppressor gene, p47Ing3

ABSTRACT

The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patentapplication Ser. No. 60/181,292, filed on Feb. 9, 2000, the teachings ofwhich are herein incorporated by reference.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH AND DEVELOPMENT

Not applicable.

FIELD OF THE INVENTION

This invention relates to isolated nucleic acid and amino acid sequencesof novel human tumor suppressors, antibodies to such tumor suppressors,methods of detecting such nucleic acids and proteins, methods ofscreening for modulators of tumor suppressors, and methods of diagnosingand treating tumors with such nucleic acids and proteins.

BACKGROUND OF THE INVENTION

Certain tumors, benign, premalignant, and malignant, are known to havegenetic components. Mutations or inactivation of “tumor suppressor”genes causes some of these tumors. In normal cells, the tumor suppressorgenes are involved in the regulation of cell growth and proliferationand in the control of cellular aging, anchorage dependence andapoptosis. When the tumor suppressor genes are mutated or inactivated,cells are transformed and become immortalized or tumorigenic. Thesetransformed cells can be reverted back to the normal phenotype (i.e.,the cell growth rate is suppressed) by introducing the wildtypesuppressor genes.

The first tumor suppressor gene identified was the nuclearphosphoprotein, retinoblastoma gene (Rb). Retinoblastoma is a malignanttumor of the sensory layer of the retina, and often occurs bilaterallyduring childhood. Retinoblastoma exhibits a familial tendency, but itcan be acquired. Mutations in the Rb gene and inactivation of itsproduct have been shown to be involved in other tumors, such as bladder,breast, and small cell lung carcinomas, osteosarcomas, and soft tissuesarcomas. It was demonstrated that reconstitution of Rb-deficient tumorcells with the wildtype Rb leads to the suppression of growth rate ortumorigenicity (Huang et al., Science 242:1563-1566 (1988)). This resultprovides direct evidence that Rb protein is a tumor suppressor.

Another well-characterized tumor suppressor is the gene for the nuclearphosphoprotein, p53. More than half of all human cancers are associatedwith mutations in the tumor suppressor gene p53 (see, e.g., Hollstein etal., Science 253:49-53 (1991); Caron de Fronmentel & Soussi, GenesChromosom. Cancer 4: 1-15; Harris & Hollstein, N. Engl. J. Med.329:1318-1327 (1993); Greenblatt et al., Cancer Res. 54:4855-4878(1994)). Mutations in p53 often appear to be a critical step in thepathogenesis and progression of tumors. For example, missense mutationsof p53 occur in tumors of the colon, lung, breast, ovary, bladder, andseveral other organs. Alternatively, inactivation of the wildtype p53proteins in cells can cause tumors. For example, certain strains ofhuman papillomavirus (HPV) are known to interfere with the p53 proteinfunction, because the virus produces a protein, E6, which promotes thedegradation of the p53 protein.

Recently, another tumor suppressor gene, p33ING1, has been identified.p33ING1 directly cooperates with tumor suppressor gene p53 in growthregulation (Garkavtsev et al., Nature Genetics 14:415-420 (1996);Garkavtsev et al., Nature 391:295-298 (1998); GenBank Accession No.AF044076; SEQ ID NO: 8). Neither of the two genes can alone cause growthinhibition when the other one is suppressed (Garkavtsev et al. (1998),supra). According to immunoprecipitation studies, p33ING1 proteinsmodulate the p53 activity through physical interaction. It has been alsoreported that some neuroblastoma cells have a mutation of the p33ING1gene, and some breast cancer cell lines exhibit reduced expression ofp33ING1 (Garkavtsev et al. (1996), supra). A tumor suppressor gene withhomology to p33ING1, p33ING2, has also been cloned and characterized(See Harris and Nagashima, U.S. Provisional Patent Application No.60/121,891, filed on Feb. 26, 1999; SEQ ID NOS: 6 and 7).

Cancer remains a major public concern. Although epidemiological andcytogenetic studies demonstrated that a number of recessive geneticmutations are involved in various cancers, only a limited number oftumor suppressors have been identified. Therefore, there is a need toidentify and isolate other tumor suppressor genes. The identificationand isolation of new tumor suppressor genes would allow aid indiagnosis, prevention, and treatment of tumors and cancers.

SUMMARY OF THE INVENTION

The present invention provides a method for identifying a compound thatmodulates p47ING3, the method comprising the steps of: (i) contactingthe compound with a eukaryotic host cell or cell membrane in which hasbeen expressed a tumor suppressor polypeptide (p47ING3), thepolypeptide: (a) having greater than about 70% amino acid sequenceidentity to a polypeptide having a sequence of SEQ ID NO:1; and, (b)selectively binding to polyclonal antibodies generated against SEQ IDNO:1; and (ii) determining the functional effect of the compound uponthe cell or cell membrane expressing the polypeptide.

In one embodiment, the functional effect is determined by measuringchanges in cell growth.

In another aspect, the present invention provides a method of inhibitingcellular proliferation, the method comprising transducing a cell with anexpression vector, the vector comprising a nucleic acid encoding a tumorsuppressor polypeptide (p47ING3), the polypeptide: (i) having greaterthan about 70% amino acid sequence identity to a polypeptide having asequence of SEQ ID NO:1; and, (ii) selectively binding to polyclonalantibodies generated against SEQ ID NO:1.

In another aspect, the present invention provides a method of detectingthe presence or absence of p47ING3 in tumorigenic mammalian tissue, themethod comprising the steps of: (i) isolating a tumorigenic sample; (ii)contacting the tumorigenic sample with a p47ING3-specific reagent thatselectively associates with p47ING3; and (iii) detecting the level ofp47ING3-specific reagent that selectively associates with thetumorigenic sample.

In one embodiment, the p47ING3-specific reagent is selected from thegroup consisting of a p47ING3-specific antibody, a p47ING3-specificprimer; and a p47ING3-specific nucleic acid probe.

In another aspect, the present invention provides a for an isolatednucleic acid encoding a tumor suppressor polypeptide (p47ING3), thenucleic acid comprising the nucleic acid sequence of SEQ ID NO: 2.

Also, the present invention provides an expression vector comprising thenucleic acid of SEQ ID NO: 2. In one embodiment, a host cell istransfected with an expression vector comprising the nucleic acid of SEQID NO:2.

In another aspect, the present invention provides an isolated tumorsuppressor polypeptide (p47ING3), the polypeptide comprising an aminoacid sequence of SEQ ID NO: 1.

The present invention further provides an antibody that selectivelybinds to a p47ING3 polypeptide of SEQ ID NO: 1. In one embodiment, theantibody is polyclonal.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates binding specificities of polyclonal antibodies forp47ING3 raised against SEQ ID NO: 5 by Western blot analysis. Themolecular sizes of standards are indicated in kDa on the left handborder of the gel. The proteins were produced using the TNT T7 QuickCoupled Transcription/Translation System, Cat. # L1170 from PromegaCorporation of Madison, Wis.

FIG. 2 illustrates binding specificities of polyclonal antibodies forp47ING3 raised against SEQ ID NO: 9 by Western blot analysis. Themolecular sizes of standards are indicated in kDa on the right handborder of FIG. 2. The proteins were produced using the TNT T7 QuickCoupled Transcription/Translation System, Cat. # L1170 from PromegaCorporation of Madison, Wis. The proteins were electrophoresed andWestern blotted. The Western blot was incubated with an anti-p47ING3antibody (diluted 1:200) raised against SEQ ID NO: 9. The presence ofthe p47ING3 immunoreactive bands was visualized with a goat anti-rabbitIgG-HRP (1:2000 dilution) (Santa Cruz Biotechnology) and ECL WesternBlotting Detection Reagents (Amersham Pharmacia Biotech, RPN2106). Theblot was then subjected to autoradiography using Hyperfilm ECL (AmershamPharmacia Biotech, RPN2103K).

FIG. 3 illustrates that p47ING3 inhibits the cell growth of the humancolon carcinoma RKO cell line by colony formation assay. The left handpanel shows RKO cells transfected with the parent vector pcDNA3.1 andthe right hand panel shows RKO cells transfected with a vector thatencodes for p47ING3, pcDNA3.1-p47ING3.

FIG. 4 shows a FACS analysis of the RKO (human colon carcinoma) cellstransfected with pcDNA3.1 (top panel) or pcDNA3.1-p47ING3 (bottompanel). The cells were co-transfected with the plasmid pEGFP-F. Thecells were stained with propidium iodide. The cells were then gated forGFP fluorescence using FACscan.

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

The present invention provides for the first time nucleic acids andpolypeptides of a new tumor suppressor called p47ING3. The presentinvention also provides antibodies which specifically hybridize to ap47ING3 protein. These nucleic acids and the polypeptides they encodeare tumor suppressors that are involved in the regulation of cellproliferation and in the control of cellular aging, anchoragedependence, and apoptosis.

The present invention also provides methods of screening for modulators(e.g., activators, inhibitors, stimulators, enhancers, agonists, andantagonists) of these novel p47ING3 proteins. Such modulators are usefulfor pharmacological and genetic modulation of cell growth and tumorsuppression. The invention thus provides assays for tumor suppressionand cell growth, where p47ING3 acts as a direct or indirect reportermolecule for measuring the effect of modulators on cell growth or tumorsuppression. These assays can measure various parameters that areaffected by the p47ING3 activity, e.g., cell growth on soft agar,contact inhibition and density limitation of growth, growth factor orserum dependence, tumor specific markers levels, invasiveness intoMatrigel, tumor growth in vivo, arrest of cells in G₀/G₁ phase of thecell-cycle, p47ING3 protein or mRNA levels, transcriptional activationor repression of a reporter gene, and the like.

The present invention also provides methods of inhibiting cellproliferation of a cell by transducing the cell with an expressionvector containing p47ING3 nucleic acids. The transduced cell may have amissense or null endogenous p47ING3 phenotype or a mutation in anothertumor suppressor gene. Expression of wildtype p47ING3 restores cellgrowth regulation and prevents the development of tumor. For example,p47ING3 nucleic acids can be used to treat cancer or other cellproliferative diseases, such as hyperplasia, in patients.

Finally, the invention provides for methods of detecting p47ING3 ornucleic acid and protein expression, allowing investigation of cellgrowth regulation and tumor suppression. Furthermore, p47ING3 nucleicacid and protein expression can be used to diagnose cancer in patientswho have a defect in one or more copies of p47ING3 in their genome.

Functionally, p47ING3 represents a protein having a molecular weight ofapproximately 40-47 kDa. It is involved in the regulation of cellproliferation and in the control of cellular aging, anchorage andapoptosis.

Structurally, the nucleotide sequence of p47ING3 (see, e.g., SEQ IDNO:2, isolated from a human) encodes a polypeptide of approximately 418amino acids with a predicted molecular weight of approximately 47 kDa(see, e.g., SEQ ID NO:1). Related p47ING3 genes from other species shareat least about 70% amino acid identity over an amino acid region of atleast about 25 amino acids in length, preferably 50 to 100 amino acidsin length.

Specific regions of the p47ING3 nucleotide and amino acid sequences maybe used to identify polymorphic variants, interspecies homologs, andalleles of p47ING3. This identification can be made in vitro, e.g.,under stringent hybridization conditions or with PCR and sequencing, orby using the sequence information in a computer system for comparisonwith other nucleotide or amino acid sequences. Typically, identificationof polymorphic variants and alleles of p47ING3 is made by comparing anamino acid sequence of about 25 amino acids or more, preferably 50-100amino acids. Amino acid identity of approximately at least 70% or above,preferably 80%, most preferably 90-95% or above typically demonstratesthat a protein is a polymorphic variant, interspecies homolog, or alleleof p47ING3. Sequence comparison can be performed using any of thesequence comparison algorithms discussed below. Antibodies that bindspecifically to p47ING3 or a conserved region thereof can also be usedto identify alleles, interspecies homologs, and polymorphic variants.

Polymorphic variants, interspecies homologs, and alleles of p47ING3 areconformed by examining the effect of putative p47ING3 expression on cellgrowth and tumor suppression using the methods and assays describedherein. Typically, p47ING3 having the amino acid sequence of SEQ ID NO:1 is used as a positive control. For example, immunoassays usingantibodies directed against the amino acid sequence of SEQ ID NOS: 1, 5,or 9 can be used to demonstrate the identification of a polymorphicvariant or allele of p47ING3. Alternatively, p47ING3 having the nucleicacid sequences of SEQ ID NO:2 is used as a positive control, e.g., in insitu hybridization with SEQ ID NO:2 to demonstrate the identification ofa polymorphic variant or allele of p47ING3. The polymorphic variants,alleles and interspecies homologs of p47ING3 are expected to retain theability to inhibit cell proliferation and tumor suppression. Thesefunctional characteristics can be tested using various assays, such assoft agar assay, contact inhibition and density limitation of growthassay, growth factor or serum dependence assay, tumor specific markersassay, invasiveness assay, tumor growth assay, etc.

p47ING3 nucleotide and amino acid sequence information may also be usedto construct models of tumor suppressor polypeptides in a computersystem. These models are subsequently used to identify compounds thatcan activate or inhibit p47ING3. Such compounds that modulate theactivity of p47ING3 can be used to investigate the role of p47ING3 ininhibition of cell proliferation and tumor suppression or can be used astherapeutics.

Isolation of p47ING3 provides a means for assaying for modulators ofp47ING3. p47ING3 is useful for testing modulators using in vivo and invitro expression that measure various parameters, e.g., cell growth onsoft agar, contact inhibition and density limitation of growth, growthfactor or serum dependence, tumor specific markers levels, invasivenessinto Matrigel, tumor growth in vivo, p47ING3 protein or mRNA levels,transcriptional activation or repression of a reporter gene, and thelike. Such modulators identified using p47ING3 can be used to study cellgrowth regulation and tumor suppression, and further to treat cancer.

Methods of detecting p47ING3 nucleic acids and expression of p47ING3 arealso useful for to diagnose various cancers or tumors by using assayssuch as northern blotting, dot blotting, in situ hybridization, RNaseprotection, and the like. Chromosome localization of the genes encodinghuman p47ING3 can also be used to identify diseases, mutations, andtraits caused by and associated with p47ING3. Techniques, such as highdensity oligonucleotide arrays (GeneChip™, Affymetrix), can be also beused to screen for mutations, polymorphic variants, alleles andinterspecies homologs of p47ING3.

II. Definitions

As used herein, the following terms have the meanings ascribed to themunless specified otherwise.

The term “tumor suppressor” refers to a gene, or the protein it encodes,that in its wildtype form has the ability to suppress, prevent, ordecrease cell transformation. Tumor suppressor genes are genes thatencode protein(s) that regulate cell growth and proliferation directlyor indirectly, e.g., p53, Rb, and the like. If a tumor suppressor geneis damaged (e.g., by radiation, a carcinogen or inherited, orspontaneous mutation), it may lose its wildtype ability to regulate cellgrowth and proliferation, and the cells may become transformed orpre-disposed to transformation.

“p47ING” refers to a family of tumor suppressor nucleic acids orpolypeptides having a molecular weight of approximately 40-47 kDa. Theyencode a nuclear protein which is involved in the regulation of cellgrowth and proliferation and in the control of cellular aging, anchorageand apoptosis.

The term “p47ING3” therefore refers to polymorphic variants, alleles,interspecies homologs, and mutants that: (1) have about 70% amino acidsequence identity, preferably about 80-90% amino acid sequence identityto SEQ ID NO:1 over a window of about at least 50-100 amino acids; (2)binds to polyclonal antibodies raised against an immunogen comprising anamino acid sequence selected from the group consisting of SEQ ID NO:1and conservatively modified variants thereof, but does not bind topolyclonal antibodies raised against an immunogen comprising an aminoacid sequence selected from the group consisting of SEQ ID NO:8 or SEQID NO: 6 and conservatively modified variants thereof; (3) specificallyhybridize (with a size of at least about 500, preferably at least about900 nucleotides) under stringent hybridization conditions to a sequenceselected from the group consisting of SEQ ID NO:2, and conservativelymodified variants thereof; or (4) are amplified by primers thatspecifically hybridize under stringent conditions to the same sequenceas a degenerate primers sets encoding SEQ ID NOS:3 and 4.

A “test compound is able to modulate a p47ING3 activity” if the testcompound can increase or decrease a property associated with p47ING3.

A “cell expresses p47ING3 above basal levels” when the cell producesp47ING3 protein or mRNA in amounts greater than amounts produced in theparent cell or the untransfected cell. The amount of p47ING3 protein ormRNA can be determined using methods known in the art, such as Westernblots or Northern blots, respectively.

The term “modulate” refers to an increase or decrease in a parameterthat is being measured.

A “p47ING3 activity” can include, but is not limited to p47ING3 mediatedcell-cycle arrest, p47ING3 induced change in cell growth, p47ING3mediated decrease of colony formation. These properties can be assayedby comparing the effect of the test compound on a cell that does notexpress p47ING3 above basal levels with a cell that does express p47ING3above basal levels. Examples of assays include, but are not limited tosoft agar assay, cell cycle arrest assay, colony formation assay,contact inhibition and density limitation of growth assay, growth factoror serum dependence assay, anchorage dependence assay, tumor specificmarkers assay, invasiveness assay, tumor growth assay, p47ING3 proteinand mRNA level assays, transcriptional activation or repression of areporter gene assay, and the like, in vitro, in vivo, and ex vivo.

A “test compound” can essentially be any compound, such as achemotherapeutic, a peptide, a hormone, a nucleic acid and the like.

The phrases “polymorphic variant” and “allele” refer to forms of p47ING3that occur in a population (or among populations) and that maintainwildtype p47ING3 activity as measured using one of the assays describedherein.

The term “mutant” of p47ING3 refers to those mutants which areexperimentally made or those which are found in tumor or cancer cells.Mutants of p47ING3 can be due to, e.g., truncation, elongation,substitution of amino acids, deletion, insertion, or lack of expression(e.g., due to promoter or splice site mutations, etc.). A mutant hasactivity that differs from the activity of wildtype p47ING3 by at leastabout 20% as measured using an assay described herein. For example, amutant of p47ING3 can have a null mutation which results in absence ofnormal gene product at the molecular level or an absence of function atthe phenotypic level. Another example is a missense mutation of p47ING3,where a substitution of amino acid(s) results in a change in theactivity of the protein.

The phrase “missense or null endogenous p47ING3 phenotype” of a celltherefore refers to p47ING3 has a missense or null mutation so that thecell has a phenotype (e.g., soft agar growth, contact inhibition anddensity limitation of growth, etc.) which differs from a cell having awildtype p47ING3.

“p33ING2” and “p33ING1” are members of the “p33ING” family, whichmembers are encoded by different genes (i.e., mapped to differentregions on the chromosome). p33ING2 is mapped to human chromosome 7q31.

An “expression vector” is a nucleic acid construct, generatedrecombinantly or synthetically, with a series of specified nucleic acidelements that permit transcription of a particular nucleic acid in ahost cell. The expression vector can be part of a plasmid, virus, ornucleic acid fragment. Typically, the expression vector includes anucleic acid to be transcribed operably linked to a promoter.

The term “transfect” or “transduce” refers to any way of getting anucleic acid across a cell membrane, including electroporation,biolistics, injection, plasmid transfection, lipofection, viraltransduction, lipid-nucleic acid complexes, naked DNA, etc

A “host cell” is a naturally occurring cell or a transformed cell thatcontains an expression vector and supports the replication or expressionof the expression vector. Host cells may be cultured cells, explants,cells in vivo, and the like. Host cells may be prokaryotic cells such asE. coli, or eukaryotic cells such as yeast, insect, amphibian, ormammalian cells such as CHO, HeLa, HCT116, RK0 cells, and the like.

“Tumorigenic sample” as used herein is a sample of biological tissue orfluid that contains nucleic acids or polypeptides of p47ING3. Thebiological tissue comprises cancer cells, transformed cells, a tumor, atumor cell and the like. The fluid comprises a solution obtained from ananimal comprising cancer cells, transformed cells, a tumor, tumor cellsand the like. Such samples include, but are not limited to, tissueisolated from humans, mice, and rats. Tumorigenic samples may alsoinclude sections of tissues such as frozen sections taken fromhistological purposes. A tumorigenic sample is typically obtained from aeukaryotic organism, such as insects, protozoa, birds, fish, reptiles,and preferably a mammal such as rat, mouse, cow, dog, guinea pig, orrabbit, and most preferably a primate such as chimpanzees or humans.

“Tumor cell” refers to precancerous, cancerous, and normal cells in atumor.

“Cancer cells”, “transformed” cells or “tansformation” in tissueculture, refers to spontaneous or induced phenotypic changes that do notnecessarily involve the uptake of new genetic material. Althoughtransformation can arise from infection with a transforming virus andincorporation of new genomic DNA, or uptake of exogenous DNA, it canalso arise spontaneously or following exposure to a carcinogen, therebymutating an endogenous gene. Transformation is associated withphenotypic changes, such as immortalization of cells, aberrant growthcontrol, and/or malignancy (see, Freshney, Culture of Animal Cells aManual of Basic Technique (3^(rd) ed. 1994)).

“Inhibitors,” “activators,” and “modulators” of p47ING3 refer toinhibitory, activating, or modulatory molecules identified using invitro and in vivo assays for tumor suppression, e.g., ligands, agonists,antagonists, and their homologs and mimetics. Inhibitors are compoundsthat decrease, block, prevent, delay activation, inactivate,desensitize, or down regulate tumor suppression, e.g., antagonists.Activators are compounds that increase, activate, facilitate, enhanceactivation, sensitize or up regulate tumor suppression, e.g., agonists.Modulators are inhibitors and activators and include geneticallymodified versions of p47ING3, e.g., with altered activity, as well asnaturally occurring and synthetic ligands, antagonists, agonists, smallchemical molecules and the like. Such assays for modulators include,e.g., expressing p47ING3 in cells, applying putative modulatorcompounds, and then determining the functional effects on inhibition ofcell proliferation or tumor suppression. Compounds identified by theseassays are used to modulate tumor suppression effect of p47ING3.

Samples or assays comprising p47ING3 that are treated with a potentialmodulator are compared to control samples without the inhibitor,activator, or modulator. Control samples (untreated with inhibitors) areassigned a relative p47ING3 activity value of 100%. Inhibition ofp47ING3 is achieved when the p47ING3 activity value relative to thecontrol is about 90%, preferably 50%, more preferably 25-0%. Activationof p47ING3 is achieved when the p47ING3 activity value relative to thecontrol (untreated with activators) is 110%, more preferably 150%, morepreferably 200-500%, more preferably 1000-3000% higher.

The phrase “changes in cell growth” refers to any change in cell growthand proliferation characteristics in vitro or in vivo, such as formationof foci, anchorage independence, semi-solid or soft agar growth, changesin contact inhibition and density limitation of growth, loss of growthfactor or serum requirements, changes in cell morphology, gaining orlosing immortalization, gaining or losing tumor specific markers,ability to form or suppress tumors when injected into suitable animalhosts, and/or immortalization of the cell. See, e.g., Freshney, Cultureof Animal Cells a Manual of Basic Technique, 3^(rd) ed. (Wiley-Liss,Inc. 1994), pp. 231-241, herein incorporated by reference.

The term “recombinant” when used with reference, e.g., to a cell, ornucleic acid, protein, or vector, indicates that the cell, nucleic acid,protein or vector, has been modified by the introduction of aheterologous nucleic acid or protein or the alteration of a nativenucleic acid or protein, or that the cell is derived from a cell somodified. Thus, for example, recombinant cells express genes that arenot found within the native (non-recombinant) form of the cell orexpress native genes that are otherwise abnormally expressed, underexpressed or not expressed at all.

A “promoter” is defined as an array of nucleic acid control sequencesthat direct transcription of a nucleic acid. As used herein, a promoterincludes necessary nucleic acid sequences near the start site oftranscription, such as, in the case of a polymerase II type promoter, aTATA element. A promoter also optionally includes distal enhancer orrepressor elements, which can be located as much as several thousandbase pairs from the start site of transcription.

A “constitutive” promoter is a promoter that is active under mostenvironmental and developmental conditions. An “inducible” promoter is apromoter that is active under environmental or developmental regulation.

The term “operably linked” refers to a functional linkage between anucleic acid expression control sequence (such as a promoter, or arrayof transcription factor binding sites) and a second nucleic acidsequence, wherein the expression control sequence directs transcriptionof the nucleic acid corresponding to the second sequence.

The term “heterologous” when used with reference to portions of anucleic acid indicates that the nucleic acid comprises two or moresubsequences that are not found in the same relationship to each otherin nature. For instance, the nucleic acid is typically recombinantlyproduced, having two or more sequences from unrelated genes arranged tomake a new functional nucleic acid, e.g., a promoter from one source anda coding region from another source. Similarly, a heterologous proteinindicates that the protein comprises two or more subsequences that arenot found in the same relationship to each other in nature (e.g., afusion protein).

A “label” is a composition detectable by spectroscopic, photochemical,biochemical, immunochemical, or chemical means. For example, usefullabels include ³²P, fluorescent dyes, electron-dense reagents, enzymes(e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptensand proteins for which antisera or monoclonal antibodies are available(e.g., the polypeptide of SEQ ID NO:1 can be made detectable, e.g., byincorporating a radiolabel into the peptide, and used to detectantibodies specifically reactive with the peptide).

The terms “isolated,” “purified,” or “biologically pure” refer tomaterial that is substantially or essentially free from components whichnormally accompany it as found in its native state. Purity andhomogeneity are typically determined using analytical chemistrytechniques such as polyacrylamide gel electrophoresis or highperformance liquid chromatography. A protein that is the predominantspecies present in a preparation is substantially purified. Inparticular, an isolated p47ING3 nucleic acid is separated from openreading frames that flank the p47ING3 gene and encode proteins otherthan p47ING3. The term “purified” denotes that a nucleic acid proteingives rise to essentially one band in an electrophoretic gel.Particularly, it means that the nucleic acid or protein is at least 85%pure, more preferably at least 95% pure, and most preferably at least99% pure.

“Nucleic acid” refers to deoxyribonucleotides or ribonucleotides andpolymers thereof in either single- or double-stranded form. The termencompasses nucleic acids containing known nucleotide analogs ormodified backbone residues or linkages, which are synthetic, naturallyoccurring, and non-naturally occurring, which have similar bindingproperties as the reference nucleic acid, and which are metabolized in amanner similar to the reference nucleotides. Examples of such analogsinclude, without limitation, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides,peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence alsoimplicitly encompasses conservatively modified variants thereof (e.g.,degenerate codon substitutions) and complementary sequences, as well asthe sequence explicitly indicated. The term nucleic acid is usedinterchangeably with gene, cDNA, mRNA, oligonucleotide, andpolynucleotide.

The terms “polypeptide,” “peptide,” and “protein” are usedinterchangeably herein to refer to a polymer of amino acid residues. Theterms apply to amino acid polymers in which one or more amino acidresidue is an analog or mimetic of a corresponding naturally occurringamino acid, as well as to naturally occurring amino acid polymers.

The term “amino acid” refers to naturally occurring and synthetic aminoacids, as well as amino acid analogs and amino acid mimetics thatfunction in a manner similar to the naturally occurring amino acids.Naturally occurring amino acids are those encoded by the genetic code,as well as those amino acids that are later modified, e.g.,hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acidanalogs refers to compounds that have the same basic chemical structureas a naturally occurring amino acid, i.e., an α carbon that is bound toa hydrogen, a carboxyl group, an amino group, and an R group (e.g.,homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium). Such analogs have modified R groups (e.g., norleucine) ormodified peptide backbones, but retain the same basic chemical structureas a naturally occurring amino acid. Amino acid mimetics refer tochemical compounds that have a structure that is different from thegeneral chemical structure of an amino acid, but that function in amanner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly knownthree letter symbols or by the one-letter symbols recommended by theIUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise,may be referred to by their commonly accepted single-letter codes.

“Conservatively modified variants” applies to both amino acid andnucleic acid sequences. With respect to particular nucleic acidsequences, conservatively modified variants refer to those nucleic acidswhich encode identical or essentially identical amino acid sequences, orwhere the nucleic acid does not encode an amino acid sequence, toessentially identical sequences. Specifically, degenerate codonsubstitutions may be achieved by generating sequences in which the thirdposition of one or more selected (or all) codons is substituted withmixed-base and/or deoxyinosine residues (Batzer et al., Nucleic AcidRes. 19:5081 (1991); Ohtsuka et al., J. Biol Chem. 260:2605-2608 (1985);Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). Because of thedegeneracy of the genetic code, a large number of functionally identicalnucleic acids encode any given protein. For instance, the codons GCA,GCC, GCG and GCU all encode the amino acid alanine. Thus, at everyposition where an alanine is specified by a codon, the codon can bealtered to any of the corresponding codons described without alteringthe encoded polypeptide. Such nucleic acid variations are “silentvariations,” which are one species of conservatively modifiedvariations. Every nucleic acid sequence herein which encodes apolypeptide also describes every possible silent variation of thenucleic acid. One of skill will recognize that each codon in a nucleicacid (except AUG, which is ordinarily the only codon for methionine, andTGG, which is ordinarily the only codon for tryptophan) can be modifiedto yield a functionally identical molecule. Accordingly, each silentvariation of a nucleic acid which encodes a polypeptide is implicit ineach described sequence.

As to amino acid sequences, one of skill will recognize that individualsubstitutions, deletions or additions to a nucleic acid, peptide,polypeptide, or protein sequence which alters, adds or deletes a singleamino acid or a small percentage of amino acids in the encoded sequenceis a “conservatively modified variant” where the alteration results inthe substitution of an amino acid with a chemically similar amino acid.Conservative substitution tables providing functionally similar aminoacids are well known in the art. Such conservatively modified variantsare in addition to and do not exclude polymorphic variants, interspecieshomologs, and alleles of the invention.

The following groups each contain amino acids that are conservativesubstitutions for one another:

-   1) Alanine (A), Glycine (G);-   2) Serine (S), Threonine (T);-   3) Aspartic acid (D), Glutamic acid (E);-   4) Asparagine (N), Glutamine (Q);-   5) Cysteine (C), Methionine (M);-   6) Arginine (R), Lysine (K), Histidine (H);-   7) Isoleucine (I), Leucine (L), Valine (V); and-   8) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).    (see, e.g., Creighton, Proteins (1984)).

The terms “identical” or percent “identity,” in the context of two ormore nucleic acids or polypeptide sequences, refer to two or moresequences or subsequences that are the same or have a specifiedpercentage of amino acid residues or nucleotides (i.e., 70% identity)that are the same, when compared and aligned for maximum correspondenceover a comparison window, as measured using one of the followingsequence comparison algorithms or by manual alignment and visualinspection. Such sequences are then said to be “substantiallyidentical.” This definition also refers to the complement of a testsequence. Preferably, the percent identity exists over a region of thesequence that is at least about 25 amino acids in length, morepreferably over a region that is 50 or 100 amino acids in length.

For sequence comparison, one sequence acts as a reference sequence, towhich test sequences are compared. When using a sequence comparisonalgorithm, test and reference sequences are entered into a computer,subsequence coordinates are designated, if necessary, and sequencealgorithm program parameters are designated. Default program parameterscan be used, or alternative parameters can be designated. The sequencecomparison algorithm then calculates the percent sequence identities forthe test sequences relative to the reference sequence, based on theprogram parameters.

A “comparison window,” as used herein, includes reference to a segmentof contiguous positions selected from the group consisting of from 20 to600, usually about 50 to about 200, more usually about 100 to about 150in which a sequence may be compared to a reference sequence of the samenumber of contiguous positions after the two sequences are optimallyaligned. Methods of alignment of sequences for comparison are well-knownin the art. Optimal alignment of sequences for comparison can beconducted, e.g., by the local homology algorithm of Smith & Waterman,Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm ofNeedleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search forsimilarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA85:2444 (1988), by computerized implementations of these algorithms(GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics SoftwarePackage, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or bymanual alignment and visual inspection.

One example of a useful algorithm is PILEUP. PILEUP creates a multiplesequence alignment from a group of related sequences using progressive,pairwise alignments to show relationship and percent sequence identity.It also plots a tree or dendogram showing the clustering relationshipsused to create the alignment. PILEUP uses a simplification of theprogressive alignment method of Feng & Doolittle, J. Mol. Evol.35:351-360 (1987). The method used is similar to the method described byHiggins & Sharp, CABIOS 5:151-153 (1989). The program can align up to300 sequences, each of a maximum length of 5,000 nucleotides or aminoacids. The multiple alignment procedure begins with the pairwisealignment of the two most similar sequences, producing a cluster of twoaligned sequences. This cluster is then aligned to the next most relatedsequence or cluster of aligned sequences. Two clusters of sequences arealigned by a simple extension of the pairwise alignment of twoindividual sequences. The final alignment is achieved by a series ofprogressive, pairwise alignments. The program is run by designatingspecific sequences and their amino acid or nucleotide coordinates forregions of sequence comparison and by designating the programparameters. Using PILEUP, a reference sequence is compared to other testsequences to determine the percent sequence identity relationship usingthe following parameters: default gap weight (3.00), default gap lengthweight (0.10), and weighted end gaps. PILEUP can be obtained from theGCG sequence analysis software package, e.g., version 7.0 (Devereaux etal., Nucleic Acids Res. 12:387-395 (1984)).

Another example of algorithm that is suitable for determining percentsequence identity and sequence similarity is the BLAST algorithm, whichis described in Altschul et al., J. Mol. Biol. 215:403-410 (1990).Software for performing BLAST analyses is publicly available through theNational Center for Biotechnology Information (www.ncbi.nlm.nih.gov/).This algorithm involves first identifying high scoring sequence pairs(HSPs) by identifying short words of length W in the query sequence,which either match or satisfy some positive-valued threshold score Twhen aligned with a word of the same length in a database sequence. T isreferred to as the neighborhood word score threshold (Altschul et al.,supra). These initial neighborhood word hits act as seeds for initiatingsearches to find longer HSPs containing them. The word hits are extendedin both directions along each sequence for as far as the cumulativealignment score can be increased. Extension of the word hits in eachdirection are halted when: the cumulative alignment score falls off bythe quantity X from its maximum achieved value; the cumulative scoregoes to zero or below, due to the accumulation of one or morenegative-scoring residue alignments; or the end of either sequence isreached. The BLAST algorithm parameters W, T, and X determine thesensitivity and speed of the alignment. The BLAST program uses asdefaults a word length (W) of 11, the BLOSUM62 scoring matrix (seeHenikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989))alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparisonof both strands.

The BLAST algorithm also performs a statistical analysis of thesimilarity between two sequences (see, e.g., Karlin & Altschul, Proc.Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarityprovided by the BLAST algorithm is the smallest sum probability (P(N)),which provides an indication of the probability by which a match betweentwo nucleotide or amino acid sequences would occur by chance. Forexample, a nucleic acid is considered similar to a reference sequence ifthe smallest sum probability in a comparison of the test nucleic acid tothe reference nucleic acid is less than about 0.2, more preferably lessthan about 0.01, and most preferably less than about 0.001.

An indication that two nucleic acid sequences or polypeptides aresubstantially identical is that the polypeptides per se or thepolypeptides encoded by the nucleic acids (testers) are immunologicallycross reactive with the antibodies raised against the polypeptide(control) as described below. Thus, a polypeptide is typicallysubstantially identical to a second polypeptide, for example, where thetwo peptides differ only by conservative substitutions. Anotherindication that two nucleic acid sequences are substantially identicalis that the two molecules or their complements hybridize to each otherunder stringent conditions, as described below.

The phrase “selectively (or specifically) hybridizes to” refers to thebinding, duplexing, or hybridizing of a molecule only to a particularnucleotide sequence under stringent hybridization conditions when thatsequence is present in a complex mixture (e.g., total cellular orlibrary DNA or RNA).

The phrase “stringent hybridization conditions” refers to conditionsunder which a probe will hybridize to its target subsequence, typicallyin a complex mixture of nucleic acid, but to no other sequences.Stringent conditions are sequence-dependent and will be different indifferent circumstances. Longer sequences hybridize specifically athigher temperatures. An extensive guide to the hybridization of nucleicacids is found in Tijssen, Techniques in Biochemistry and MolecularBiology—Hybridization with Nucleic Probes, “Overview of principles ofhybridization and the strategy of nucleic acid assays” (1993).Generally, stringent conditions are selected to be about 5-10° C. lowerthan the thermal melting point (T_(m)) for the specific sequence at adefined ionic strength pH. The T_(m) is the temperature (under definedionic strength, pH, and nucleic concentration) at which 50% of theprobes complementary to the target hybridize to the target sequence atequilibrium (as the target sequences are present in excess, at T_(m),50% of the probes are occupied at equilibrium). Stringent conditionswill be those in which the salt concentration is less than about 1.0 Msodium ion, typically about 0.01 to 1.0 M sodium ion concentration (orother salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C. for long probes (e.g., greater than 50 nucleotides). Stringentconditions may also be achieved with the addition of destabilizingagents such as formamide. For selective or specific hybridization, apositive signal is at least two times background, preferably 10 timesbackground hybridization. Exemplary stringent hybridization conditionscan be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42°C., or, 5×SSC, 1% SDS, incubating at 65° C., with a wash in 0.2×SSC, and0.1% SDS at 65° C.

Nucleic acids that do not hybridize to each other under stringentconditions are still substantially identical if the polypeptides whichthey encode are substantially identical. This occurs, for example, whena copy of a nucleic acid is created using the maximum codon degeneracypermitted by the genetic code. In such cases, the nucleic acidstypically hybridize under moderately stringent hybridization conditions.Exemplary “moderately stringent hybridization conditions” include ahybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C.,and a wash in 1×SSC at 45° C. A positive hybridization is at least twicebackground. Those of ordinary skill will readily recognize thatalternative hybridization and wash conditions can be utilized to provideconditions of similar stringency.

A further indication that two polynucleotides are substantiallyidentical is if the reference sequence, amplified by a pair ofoligonucleotide primers or a pool of degenerate primers that encode aconserved amino acid sequence, can then be used as a probe understringent hybridization conditions to isolate the test sequence from acDNA or genomic library, or to identify the test sequence in, e.g., aNorthern or Southern blot. Alternatively, another indication that thesequences are substantially identical is if the same set of PCR primerscan be used to amplify both sequences.

“Antibody” refers to a polypeptide comprising a framework region from animmunoglobulin gene or fragments thereof that specifically binds andrecognizes an antigen. The recognized immunoglobulin genes include thekappa, lambda, alpha, gamma, delta, epsilon, and mu constant regiongenes, as well as the myriad immunoglobulin variable region genes. Lightchains are classified as either kappa or lambda. Heavy chains areclassified as gamma, mu, alpha, delta, or epsilon, which in turn definethe immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises atetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (about 25 kDa) and one“heavy” chain (about 50-70 kDa). The N-terminus of each chain defines avariable region of about 100 to 110 or more amino acids primarilyresponsible for antigen recognition. The terms variable light chain (VL)and variable heavy chain (VH) refer to these light and heavy chainsrespectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of wellcharacterized fragments produced by digestion with various peptidases.Thus, for example, pepsin digests an antibody below the disulfidelinkages in the hinge region to produce F(ab)′2, a dimer of Fab whichitself is a light chain joined to VH-CH1 by a disulfide bond. TheF(ab)′2 may be reduced under mild conditions to break the disulfidelinkage in the hinge region, thereby converting the F(ab)′2 dimer intoan Fab′ monomer. The Fab′ monomer is essentially an Fab with part of thehinge region (see Fundamental Immunology (Paul ed., 3^(rd) ed. 1993).While various antibody fragments are defined in terms of the digestionof an intact antibody, one of skill will appreciate that such fragmentsmay be synthesized de novo either chemically or by using recombinant DNAmethodology. Thus, the term antibody, as used herein, also includesantibody fragments either produced by the modification of wholeantibodies or those synthesized de novo using recombinant DNAmethodologies (e.g., single chain Fv).

For preparation of monoclonal or polyclonal antibodies, any techniqueknown in the art can be used (see, e.g., Kohler & Milstein, Nature256:495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Coleet al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R.Liss, Inc. (1985)). Techniques for the production of single chainantibodies (U.S. Pat. No. 4,946,778) can be adapted to produceantibodies to polypeptides of this invention. Also, transgenic mice, orother organisms such as other mammals, may be used to express humanizedantibodies. Alternatively, phage display technology can be used toidentify antibodies and heteromeric Fab fragments that specifically bindto selected antigens (see, e.g., McCafferty et al., Nature 348:552-554(1990); Marks et al., Biotechnology 10:779-783 (1992)).

An “anti-p47ING3” antibody is an antibody or antibody fragment thatspecifically binds a polypeptide encoded by the p47ING3 gene, cDNA, or asubsequence thereof.

An “anti-p33ING2” antibody is an antibody or antibody fragment thatspecifically binds a polypeptide encoded by the p33ING2 gene, cDNA, or asubsequence thereof.

An “anti-p33ING1” antibody is an antibody or antibody fragment thatspecifically binds to a polypeptide encoded by the p33ING1 gene, cDNA,or a subsequence thereof.

The term “immunoassay” is an assay that uses an antibody to specificallybind an antigen. The immunoassay is characterized by the use of specificbinding properties of a particular antibody to isolate, target, and/orquantify the antigen.

The phrase “specifically (or selectively) binds” to an antibody or“specifically (or selectively) immunoreactive with,” when referring to aprotein or peptide, refers to a binding reaction that is determinativeof the presence of the protein in a heterogeneous population of proteinsand other biologics. Thus, under designated immunoassay conditions, thespecified antibodies bind to p47ING3 at least two times the background,more typically 10 to 100 times background, and do not substantially bindin a significant amount to other proteins present in the sample.Specific binding to a polyclonal antibody under such conditions mayrequire an antibody that is selected for us specificity for a particularprotein. For example, polyclonal antibodies raised to p47ING3 from aspecies such as rat, mouse, or human can be selected to obtain onlythose polyclonal antibodies that are specifically immunoreactive withp47ING3 and not with other proteins, such as p33ING1 or p33ING2, exceptfor polymorphic variants and alleles of p47ING3. This selection may beachieved for polyclonal antibodies by subtracting out antibodies thatcross react with p33ING1 or p33ING2. For monoclonal antibodies, thespecificity may be achieved by using a p47ING3 specific antigen to makethe hybridomas (e.g., SEQ ID NO: 5 or SEQ ID NO: 9). For identifyingp47ING3 variants and alleles from a particular species such as a human,the selection may be achieved by subtracting out antibodies thatcross-react with p33ING2 or p33ING1 molecules, respectively, from otherspecies. For species specific monoclonal antibodies, a species specificantigen can be used to make the hybridomas. A variety of immunoassayformats may be used to select antibodies specifically immunoreactivewith a particular protein. For example, solid-phase ELISA immunoassaysare routinely used to select antibodies specifically immunoreactive witha protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual(1988) for a description of immunoassay formats and conditions that canbe used to determine specific immunoreactivity).

The phrase “selectively associates with” refers to the ability of anucleic acid to “selectively hybridize” with another as defined above,or the ability of an antibody to “selectively (or specifically) bind toa protein, as defined above.

“p47ING3-specific reagent” refers to any reagent which specificallyassociates with p47ING3. For example, it can be a p47ING3-specificantibody, a p47ING3-specific primer, or a p47ING3-specific nucleic acidprobe.

III. Isolation of the Gene Encoding p47ING3

A. General Recombinant DNA Methods

p47ING3 polypeptides and nucleic acids are used in the assays describedbelow. For example, recombinant p47ING3 can be used to make cells thatconstitutively express p47ING3. Such polypeptides and nucleic acids canbe made using routine techniques in the field of recombinant genetics.Basic texts disclosing the general methods of use in this inventioninclude Sambrook et al., Molecular Cloning, A Laboratory Manual (2^(nd)ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual(1990); and Current Protocols in Molecular Biology (Ausubel et al.,eds., 1994)).

For nucleic acids, sizes are given in either kilobases (kb) or basepairs (bp). These are estimates derived from agarose or acrylamide gelelectrophoresis, from sequenced nucleic acids, or from published DNAsequences. For proteins, sizes are given in kilodaltons (kDa) or aminoacid residue numbers. Proteins sizes are estimated from gelelectrophoresis, from sequenced proteins, from derived amino acidsequences, or from published protein sequences.

Oligonucleotides can be chemically synthesized according to the solidphase phosphoramidite triester method first described by Beaucage &Caruthers, Tetrahedron Letts. 22:1859-1862 (1981), using an automatedsynthesizer, as described in Van Devanter et al., Nucleic Acids Res.12:6159-6168 (1984). Purification of oligonucleotides is typically byeither native acrylamide gel electrophoresis or by anion-exchange HPLCas described in Pearson & Reanier, J. Chrom. 255:137-149 (1983). Thesequence of the cloned genes and synthetic oligonucleotides can beverified after cloning using, e.g., the chain termination method forsequencing double-stranded templates of Wallace et al., Gene 16:21-26(1981). Again, as noted above, companies such as Operon Technologies,Inc. provide an inexpensive commercial source for essentially anyoligonucleotide.

B. Cloning Methods for the Isolation of Nucleotide Sequences Encodingp47ING3

In general, the nucleic acid sequences encoding genes of interest, suchas p47ING3 and related nucleic acid sequence homologs, are cloned fromcDNA and genomic DNA libraries by hybridization with a probe, orisolated using amplification techniques with oligonucleotide primers.Preferably mammalian, more preferably human sequences are used. Forexample, p47ING3 sequences are typically isolated from mammalian nucleicacid (genomic or cDNA) libraries by hybridizing with a nucleic acidprobe, the sequence of which can be derived from SEQ ID NO:2 A suitabletissue from which human p47ING3 RNA and cDNA can be isolated is, e.g.,placenta, heart, brain, placenta, lung, liver, skeletal muscle, kidney,pancreas, spleen, thyroid, prostate, testis, ovary, small intestine,colon, peripheral blood cell, leukocyte. Heart, Brain, placenta, lung,liver, skeletal muscle, kidney, pancreas, spleen, thyroid, prostate,testis, ovary, small intestine, colon, peripheral blood cell, leukocyte

Amplification techniques using primers can also be used to amplify andisolate, e.g., a nucleic acid encoding p47ING3, from DNA or RNA (see,e.g. Dieffenfach & Dveksler, PCR Primer: A Laboratory Manual (1995)).These primers can be used, e.g., to amplify either the full lengthsequence or a probe of one to several hundred nucleotides, which is thenused to screen a mammalian library for the full-length nucleic acid ofchoice. For example, degenerate primer sets for p47ING3 sequences suchas MLYLEDY (SEQ ID NO:3) and RRGSRHK (SEQ ID NO:4) can be used toisolate p47ING3 nucleic acids. Nucleic acids can also be isolated fromexpression libraries using antibodies as probes. Such polyclonal ormonoclonal antibodies can be raised, e.g. using the sequence of p47ING3.

Polymorphic variants and alleles that are substantially identical to thegene of choice can be isolated using nucleic acid probes, andoligonucleotides under stringent hybridization conditions, by screeninglibraries. Alternatively, expression libraries can be used to clone,e.g., p47ING3 and p47ING3 polymorphic variants, interspecies homologs,and alleles, by detecting expressed homologs immunologically withantisera or purified antibodies made against p47ING3, which alsorecognize and selectively bind to the p47ING3 homolog.

To make a cDNA library, one should choose a source that is rich in themRNA of choice, e.g., for human p47ING3 mRNA, human colon carcinoma cellline RKO. The mRNA is then made into cDNA using reverse transcriptase,ligated into a recombinant vector, and transfected into a recombinanthost for propagation, screening and cloning. Methods for making andscreening cDNA libraries are well known (see, e.g., Gubler & Hoffman,Gene 25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra).

For a genomic library, the DNA is extracted from the tissue and eithermechanically sheared or enzymatically digested to yield fragments ofabout 12-20 kb. The fragments are then separated by gradientcentrifugation from undesired sizes and are constructed in non-lambdaexpression vectors. These vectors are packaged in vitro. Recombinantphage are analyzed by plaque hybridization as described in Benton &Davis, Science 196:180-182 (1977). Colony hybridization is carried outas generally described in Grunstein et al., Proc. Natl. Acad. Sci. USA.,72:3961-3965 (1975).

An alternative method of isolating a nucleic acid and its homologscombines the use of synthetic oligonucleotide primers and amplificationof an RNA or DNA template (see U.S. Pat. Nos. 4,683,195 and 4,683,202;PCR Protocols: A Guide to Methods and Applications (Innis et al., eds,1990)). Methods such as polymerase chain reaction (PCR) and ligase chainreaction (LCR) can be used to amplify nucleic acid sequences of, e.g.,p47ING3 directly from mRNA, from cDNA, from genomic libraries or cDNAlibraries. Degenerate oligonucleotides can be designed to amplifyp47ING3 homologs using the sequences provided herein. Restrictionendonuclease sites can be incorporated into the primers. Polymerasechain reaction or other in vitro amplification methods may also beuseful for example, to clone nucleic acid sequences that code forproteins to be expressed, to make nucleic acids to use as probes fordetecting the presence of p47ING3 encoding mRNA in physiologicalsamples, for nucleic acid sequencing, or for other purposes. Genesamplified by the PCR reaction can be purified from agarose gels andcloned into an appropriate vector.

As described above, gene expression of p47ING3 can also be analyzed bytechniques known in the art, e.g., reverse transcription and PCRamplification of mRNA, isolation of total RNA or poly A+ RNA, northernblotting, dot blotting, in situ hybridization, RNase protection, probinghigh density oligonucleotides, and the like. All of these techniques arestandard in the art.

Synthetic oligonucleotides can be used to construct recombinant genesfor use as probes or for expression of protein. This method is performedusing a series of overlapping oligonucleotides usually 40-120 bp inlength, representing both the sense and non-sense strands of the gene.These DNA fragments are then annealed, ligated and cloned.Alternatively, amplification techniques can be used with precise primersto amplify a specific subsequence of the p47ING3 nucleic acid. Thespecific subsequence is then ligated into an expression vector.

The nucleic acid encoding the protein of choice is typically cloned intointermediate vectors before transformation into prokaryotic oreukaryotic cells for replication and/or expression. These intermediatevectors are typically prokaryote vectors, e.g., plasmids, or shuttlevectors. Optionally, cells can be transfected with recombinant p47ING3operably linked to a constitutive promoter, to provide higher levels ofp47ING3 expression in cultured cells.

C. Expression in Prokaryotes and Eukaryotes

To obtain high level expression of a cloned gene or nucleic acid, suchas those cDNAs encoding p47ING3, one typically subclones p47ING3 into anexpression vector that contains a strong promoter to directtranscription, a transcription/translation terminator, and if for anucleic acid encoding a protein, a ribosome binding site fortranslational initiation.

1. Prokaryotic Expression

Suitable bacterial promoters are well known in the art and described,e.g., in Sambrook et al. and Ausubel et al. Bacterial expression systemsfor expressing the p47ING3 protein are available in, e.g., E. coli,Bacillus sp., and Salmonella (Palva et al., Gene 22:229-235 (1983)).Kits for such expression systems are commercially available. Eukaryoticexpression systems for mammalian cells, yeast, and insect cells are wellknown in the art and are also commercially available.

2. Eukaryotic Expression

A variety of methods are known in the art for expressing a gene ineukaryotes (Ausubel et al.). These methods often achieve expression of agene above basal.

a. Transfection of Cells with an Expression Cassette

Cells can be transfected with an expression cassette containing the geneof interest and a promoter. The promoter used to direct expression of aheterologous nucleic acid depends on the particular application. Thepromoter is preferably positioned about the same distance from theheterologous transcription start site as it is from the transcriptionstart site in its natural setting. As is known in the art, however, somevariation in this distance can be accommodated without loss of promoterfunction. The promoter typically cam also include elements that areresponsive to transactivation, e.g., hypoxia responsive elements, Gal4responsive elements, lac repressor responsive elements, and the like.The promoter can be constitutive or inducible, heterologous orhomologous.

In addition to the promoter, the expression vector typically contains atranscription unit or expression cassette that contains all theadditional elements required for the expression of the nucleic acid inhost cells. A typical expression cassette thus contains a promoteroperably linked, e.g., to the nucleic acid sequence encoding p47ING3,and signals required for efficient polyadenylation of the transcript,ribosome binding sites, and translation termination. The nucleic acidsequence may typically be linked to a cleavable signal peptide sequenceto promote secretion of the encoded protein by the transformed cell.Such signal peptides would include, among others, the signal peptidesfrom tissue plasminogen activator, insulin, and neuron growth factor,and juvenile hormone esterase of Heliothis virescens. Additionalelements of the cassette may include enhancers and, if genomic DNA isused as the structural gene, introns with functional splice donor andacceptor sites.

In addition to a promoter sequence, the expression cassette should alsocontain a transcription termination region downstream of the structuralgene to provide for efficient termination. The termination region may beobtained from the same gene as the promoter sequence or may be obtainedfrom different genes.

The particular expression vector used to transport the geneticinformation into the cell is not particularly critical. Any of theconventional vectors used for expression in eukaryotic or prokaryoticcells may be used. Standard bacterial expression vectors includeplasmids such as pBR322 based plasmids, pSKF, pET23D, and fusionexpression systems such as GST and LacZ. Epitope tags can also be addedto recombinant proteins to provide convenient methods of isolation,e.g., c-myc.

Expression vectors containing regulatory elements from eukaryoticviruses are typically used in eukaryotic expression vectors, e.g., SV40vectors, papilloma virus vectors, and vectors derived from Epstein-Barrvirus. Other exemplary eukaryotic vectors include pMSG, pAV009/A+,pMTO10/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowingexpression of proteins under the direction of the SV40 early promoter,SV40 later promoter, metallothionein promoter, murine mammary tumorvirus promoter, Rous sarcoma virus promoter, polyhedrin promoter, orother promoters shown effective for expression in eukaryotic cells.

Some expression systems have markers that provide gene amplificationsuch as thymidine kinase, hygromycin B phosphotransferase, anddihydrofolate reductase. Alternatively, high yield expression systemsnot involving gene amplification are also suitable, such as using abaculovirus vector in insect cells, with a p47ING3 encoding sequenceunder the direction of the polyhedrin promoter or other strongbaculovirus promoters.

The elements that are typically included in expression vectors alsoinclude a replicon that functions in E. coli, a gene encoding antibioticresistance to permit selection of bacteria that harbor recombinantplasmids, and unique restriction sites in nonessential regions of theplasmid to allow insertion of eukaryotic sequences. The particularantibiotic resistance gene chosen is not critical, any of the manyresistance genes known in the art are suitable. The prokaryoticsequences are preferably chosen such that they do not interfere with thereplication of the DNA in eukaryotic cells, if necessary.

Standard transfection methods are used to produce bacterial, mammalian,yeast or insect cell lines that express large quantities of protein,which are then purified using standard techniques (see, e.g., Colley etal., J. Biol. Chem. 264:17619-17622 (1989); Guide to ProteinPurification, in Methods in Enzymology, vol. 182 (Deutscher, ed.,1990)). Transformation of eukaryotic and prokaryotic cells are performedaccording to standard techniques (see, e.g., Morrison, J. Bact.132:349-351 (1977); Clark-Curtiss & Curtiss, Methods in Enzymology101:347-362 (Wu et al., eds, 1983).

Any of the well known procedures for introducing foreign nucleotidesequences into host cells may be used. These include the use of calciumphosphate transfection, polybrene, protoplast fusion, electroporation,liposomes, microinjection, plasma vectors, viral vectors and any of theother well known methods for introducing cloned genomic DNA, cDNA,synthetic DNA or other foreign genetic material into a host cell (see,e.g., Sambrook et al., supra). It is only necessary that the particulargenetic engineering procedure used be capable of successfullyintroducing at least one gene into the host cell capable of expressingthe protein of choice.

After the expression vector is introduced into the cells, thetransfected cells are cultured under conditions favoring expression ofthe p47ING3 protein, which is recovered from the culture using standardtechniques identified below.

b. Gene Activation

The method of gene activation can also be used to express an endogenousgene, e.g. p47ING3, above basal levels in a cell. Details of thistechnology can be found in U.S. Pat. Nos. 5,272,071, 5,641,670, EP0747485B1, EP 0505500B1). Instead of transfecting an exogenous gene inan expression cassette into a cell, these methods rely on theintroduction of nucleotide sequences into a cell that will activate theendogenous gene. The nucleotide sequences are homologously recombinedinto the cell's genome and cause an increase in the transcription of theendogenous gene.

One method involves the activation of a gene that is usuallytranscriptionally silent in the genome of a eukaryotic cell line (U.S.Pat. No. 5,641,670). Briefly, the method involves introducing apolynucleotide sequence containing a targeting sequence, a regulatorysequence, an exon, and an unpaired splice donor site. The polynucleotidesequence is introduced into the cell and homologously recombined withthe endogenous gene. The homologous recombination event permits thepolynucleotide sequence to be operably linked with the endogenous gene.The regulatory sequence is able to promote the transcription of thenormally silent endogenous gene and expression of the gene is achievedabove basal levels.

The regulatory sequence can contain one or more promoters. A variety ofpromoters can be used, such as sequences that regulated the expressionof viral genes, actin genes, immunoglobulin genes and the like. Theregulatory sequences can contain binding sites for transcriptionfactors, which serve to promote transcription of the gene that isoperably linked to the polynucleotide sequence.

IV. Purification of p47ING3

If necessary, naturally occurring or recombinant proteins can bepurified for use in functional assays, e.g., to make antibodies todetect p47ING3. Naturally occurring p47ING3 can be purified, e.g., frommammalian tissue such as heart, brain, placenta, lung, liver, skeletalmuscle, kidney, pancreas, spleen, thyroid, prostate, testis, ovary,small intestine, colon, peripheral blood cells, and leukocytes.

Recombinant p47ING3 is purified from any suitable expression system,e.g., by expressing p47ING3 in E. coli and then purifying therecombinant protein via affinity purification, e.g., by using antibodiesthat recognize a specific epitope on the protein or on part of thefusion protein, or by using glutathione affinity gel, which binds toGST. In some embodiments, the recombinant protein is a fusion protein,e.g., with GST or Gal4 at the N-terminus.

The protein of choice may be purified to substantial purity by standardtechniques, including selective precipitation with such substances asammonium sulfate; column chromatography, immunopurification methods, andothers (see, e.g., Scopes, Protein Purification: Principles and Practice(1982); U.S. Pat. No. 4,673,641; Ausubel et al., supra; and Sambrook etal., supra).

A number of procedures can be employed when recombinant protein is beingpurified. For example, proteins having established molecular adhesionproperties can be reversibly fused to p47ING3. With the appropriateligand, p47ING3 can be selectively adsorbed to a purification column andthen freed from the column in a relatively pure form. The fused proteinis then removed by enzymatic activity. Finally, p47ING3 could bepurified using immunoaffinity columns.

A. Purification of p47ING3 from Recombinant Bacteria

Recombinant proteins are expressed by transformed bacteria in largeamounts, typically after promoter induction; but expression can beconstitutive. Promoter induction with IPTG is a one example of aninducible promoter system. Bacteria are grown according to standardprocedures in the art. Fresh or frozen bacteria cells are used forisolation of protein.

Proteins expressed in bacteria may form insoluble aggregates (“inclusionbodies”). Several protocols are suitable for purification of inclusionbodies. For example, purification of inclusion bodies typically involvesthe extraction, separation and/or purification of inclusion bodies bydisruption of bacterial cells, e.g., by incubation in a buffer of 50 mMTris/HCl pH 7.5, 50 mM NaCl, 5 mM MgCl₂, 1 mM DTT, 0.1 mM ATP, and 1 mMPMSF. The cell suspension can be lysed using 2-3 passages through aFrench press, homogenized using a Polytron (Brinkman Instruments) orsonicated on ice. Alternate methods of lysing bacteria are apparent tothose of skill in the art (see, e.g., Sambrook et al., supra; Ausubel etal., supra).

If necessary, the inclusion bodies are solubilized, and the lysed cellsuspension is typically centrifuged to remove unwanted insoluble matter.Proteins that formed the inclusion bodies may be renatured by dilutionor dialysis with a compatible buffer. Suitable solvents include, but arenot limited to urea (from about 4 M to about 8 M), formamide (at leastabout 80%, volume/volume basis), and guanidine hydrochloride (from about4 M to about 8 M). Some solvents which are capable of solubilizingaggregate-forming proteins, for example SDS (sodium dodecyl sulfate),70% formic acid, are inappropriate for use in this procedure due to thepossibility of irreversible denaturation of the proteins, accompanied bya lack of immunogenicity and/or activity. Although guanidinehydrochloride and similar agents are denaturants, this denaturation isnot irreversible and renaturation may occur upon removal (by dialysis,for example) or dilution of the denaturant, allowing re-formation ofimmunologically and/or biologically active protein. Other suitablebuffers are known to those skilled in the art. The protein of choice isseparated from other bacterial proteins by standard separationtechniques, e.g., with Ni-NTA agarose resin.

Alternatively, it is possible to purify the recombinant p47ING3 proteinfrom bacteria periplasm. After lysis of the bacteria, when the proteinis exported into the periplasm of the bacteria, the periplasmic fractionof the bacteria can be isolated by cold osmotic shock in addition toother methods known to skill in the art. To isolate recombinant proteinsfrom the periplasm, the bacterial cells are centrifuged to form apellet. The pellet is resuspended in a buffer containing 20% sucrose. Tolyse the cells, the bacteria are centrifuged and the pellet isresuspended in ice-cold 5 mM MgSO₄ and kept in an ice bath forapproximately 10 minutes. The cell suspension is centrifuged and thesupernatant decanted and saved. The recombinant proteins present in thesupernatant can be separated from the host proteins by standardseparation techniques well known to those of skill in the art.

B. Standard Protein Separation Techniques for Purifying p47ING3

Solubility Fractionation

Often as an initial step, particularly if the protein mixture iscomplex, an initial salt fractionation can separate many of the unwantedhost cell proteins (or proteins derived from the cell culture media)from the recombinant protein of interest. The preferred salt is ammoniumsulfate. Ammonium sulfate precipitates proteins by effectively reducingthe amount of water in the protein mixture. Proteins then precipitate onthe basis of their solubility. The more hydrophobic a protein is, themore likely it is to precipitate at lower ammonium sulfateconcentrations. A typical protocol includes adding saturated ammoniumsulfate to a protein solution so that the resultant ammonium sulfateconcentration is between 20-30%. This concentration will precipitate themost hydrophobic of proteins. The precipitate is then discarded (unlessthe protein of interest is hydrophobic) and ammonium sulfate is added tothe supernatant to a concentration known to precipitate the protein ofinterest. The precipitate is then solubilized in buffer and the excesssalt removed if necessary, either through dialysis or diafiltration.Other methods that rely on solubility of proteins, such as cold ethanolprecipitation, are well known to those of skill in the art and can beused to fractionate complex protein mixtures.

Size Differential Filtration

The molecular weight of the protein, e.g., p47ING3, can be used toisolated it from proteins of greater and lesser size usingultrafiltration through membranes of different pore size (for example,Amicon or Millipore membranes). As a first step, the protein mixture isultrafiltered through a membrane with a pore size that has a lowermolecular weight cut-off than the molecular weight of the protein ofinterest. The retentate of the ultrafiltration is then ultrafilteredagainst a membrane with a molecular cut off greater than the molecularweight of the protein of interest. The recombinant protein will passthrough the membrane into the filtrate. The filtrate can then bechromatographed as described below.

Column Chromatography

The protein of choice can also be separated from other proteins on thebasis of its size, net surface charge, hydrophobicity, and affinity forligands. In addition, antibodies raised against proteins can beconjugated to column matrices and the proteins immunopurified. All ofthese methods are well known in the art. It will be apparent to one ofskill that chromatographic techniques can be performed at any scale andusing equipment from many different manufacturers (e.g., PharmaciaBiotech).

V. Immunological Detection of p47ING3.

In addition to the detection of p47ING3 genes and gene expression usingnucleic acid hybridization technology, one can also use immunoassays todetect p47ING3, e.g., to identify alleles, mutants, polymorphic variantsand interspecies homologs of p47ING3. Immunoassays can be used toqualitatively or quantitatively analyze p47ING3, e.g., to detectp47ING3, to measure p47ING3 activity, or to identify modulators ofp47ING3 activity. A general overview of the applicable technology can befound in Harlow and Lane, Antibodies: A Laboratory Manual (1988).

A. Antibodies to p47ING3

Methods of producing polyclonal and monoclonal antibodies that reactspecifically with p47ING3 are known to those of skill in the art (see,e.g., Coligan, Current Protocols in Immunology (1991); Harlow & Lane,supra; Goding, Monoclonal Antibodies: Principles and Practice (2^(nd)ed. 1986); and Kohler & Milstein, Nature 256:495-497 (1975). Suchtechniques include antibody preparation by selection of antibodies fromlibraries of recombinant antibodies in phage or similar vectors, as wellas preparation of polyclonal and monoclonal antibodies by immunizingrabbits or mice (see, e.g., Huse et al., Science 246:1275-1281 (1989);Ward et al., Nature 341:544-546 (1989)). In addition, as noted above,many companies, such as BMA Biomedicals, Ltd., HTI Bio-products, and thelike, provide the commercial service of making an antibody toessentially any peptide.

A number of p47ING3 comprising immunogens may be used to produceantibodies specifically reactive with p47ING3. For example, recombinantp47ING3, or antigenic fragments thereof, are isolated as describedherein. Recombinant protein can be expressed in eukaryotic orprokaryotic cells as described above, and purified as generallydescribed above. Recombinant protein is the preferred immunogen for theproduction of monoclonal or polyclonal antibodies. Alternatively, asynthetic peptide derived from the sequences disclosed herein andconjugated to a carrier protein can be used an immunogen. Naturallyoccurring protein may also be used either in pure or impure form. Theproduct is then injected into an animal capable of producing antibodies.Either monoclonal or polyclonal antibodies may be generated, forsubsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those ofskill in the art. To improve reproducibility, an inbred strain of mice(e.g., BALB/C mice) can be immunized to make the antibody; however,standard animals (mice, rabbits, etc.) used to make antibodies areimmunized with the protein using a standard adjuvant, such as Freund'sadjuvant, and a standard immunization protocol (see Harlow & Lane,supra). The animal's immune response to the immunogen preparation ismonitored by taking test bleeds and determining the titer of reactivityto the protein of choice. When appropriately high titers of antibody tothe immunogen are obtained, blood is collected from the animal andantisera are prepared. Further fractionation of the antisera to enrichfor antibodies reactive to the protein can be done if desired (seeHarlow & Lane, supra).

Monoclonal antibodies may be obtained by various techniques familiar tothose skilled in the art. Briefly, spleen cells from an animal immunizedwith a desired antigen are immortalized, commonly by fusion with amyeloma cell (see Kohler & Milstein, Eur. J. Immunol. 6:511-519 (1976)).Alternative methods of immortalization include transformation withEpstein Barr Virus, oncogenes, or retroviruses, or other methods wellknown in the art. Colonies arising from single immortalized cells arescreened for production of antibodies of the desired specificity andaffinity for the antigen, and yield of the monoclonal antibodiesproduced by such cells may be enhanced by various techniques, includinginjection into the peritoneal cavity of a vertebrate host.Alternatively, one may isolate DNA sequences which encode a monoclonalantibody or a binding fragment thereof by screening a DNA library fromhuman B cells according to the general protocol outlined by Huse et al.,Science 246:1275-1281 (1989).

Monoclonal antibodies and polyclonal sera are collected and titeredagainst the immunogen protein in an immunoassay, for example, a solidphase immunoassay with the immunogen immobilized on a solid support.Typically, polyclonal antisera with a titer of 10⁴ or greater areselected and tested for their cross reactivity against non-p47ING3proteins or even other related proteins, e.g., from other organisms,using a competitive binding immunoassay. Specific polyclonal antiseraand monoclonal antibodies will usually bind with K_(D) of at least about0.1 mM, more usually at least about 1 μM, preferably at least about 0.1μM or better, and most preferably, 0.01 μM or better.

Once p47ING3 specific antibodies are available, these proteins can bedetected by a variety of immunoassay methods. For a review ofimmunological and immunoassay procedures, see Basic and ClinicalImmunology (Stites & Terr eds., 7^(th) ed. 1991). Moreover, theimmunoassays of the present invention can be performed in any of severalconfigurations, which are reviewed extensively in Enzyme Immunoassay(Maggio, ed., 1980); and Harlow & Lane, supra.

B. Immunological Binding Assays

p47ING3 can be detected and/or quantified using any of a number of wellrecognized immunological binding assays (see, e.g., U.S. Pat. Nos.4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of thegeneral immunoassays, see also Methods in Cell Biology: Antibodies inCell Biology, volume 37 (Asai, ed. 1993); Basic and Clinical Immunology(Stites & Terr, eds., 7th ed. 1991). Immunological binding assays (orimmunoassays) typically use an antibody that specifically binds to aprotein or antigen of choice (in this case p47ING3, or antigenicfragments thereof). The antibody may be produced by any of a number ofmeans well known to those of skill in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to andlabel the complex formed by the antibody and antigen. The labeling agentmay itself be one of the moieties comprising the antibody/antigencomplex. Thus, the labeling agent may be a labeled p47ING3 polypeptideor a labeled anti-p47ING3 antibody. Alternatively, the labeling agentmay be a third moiety, such a secondary antibody, that specificallybinds to the antibody/antigen complex (a secondary antibody is typicallyspecific to antibodies of the species from which the first antibody isderived). Other proteins capable of specifically binding immunoglobulinconstant regions, such as protein A or protein G may also be used as thelabel agent. These proteins exhibit a strong non-immunogenic reactivitywith immunoglobulin constant regions from a variety of species (see,e.g., Kronval et al., J. Immunol. 111:1401-1406 (1973); Akerstrom etal., J. Immunol. 135:2589-2542 (1985)). The labeling agent can bemodified with a detectable moiety, such as biotin, to which anothermolecule can specifically bind, such as streptavidin. A variety ofdetectable moieties are well known to those skilled in the art.

Throughout the assays, incubation and/or washing steps may be requiredafter each combination of reagents. Incubation steps can vary from about5 seconds to several hours, preferably from about 5 minutes to about 24hours. However, the incubation time will depend upon the assay format,antigen, volume of solution, concentrations, and the like. Usually, theassays will be carried out at ambient temperature, although they can beconducted over a range of temperatures, such as 10° C. to 40° C.

Non-competitive Assay Formats

Immunoassays for detecting p47ING3 in samples may be either competitiveor noncompetitive. Noncompetitive immunoassays are assays in which theamount of antigen is directly measured. In one preferred “sandwich”assay, for example, the anti-antigen antibodies can be bound directly toa solid substrate on which they are immobilized. These immobilizedantibodies then capture antigen present in the test sample. Antigen thusimmobilized is then bound by a labeling agent, such as a second antibodybearing a label. Alternatively, the second antibody may lack a label,but it may, in turn, be bound by a labeled third antibody specific toantibodies of the species from which the second antibody is derived. Thesecond or third antibody is typically modified with a detectable moiety,such as biotin, to which another molecule specifically binds, e.g.,streptavidin, to provide a detectable moiety.

Competitive Assay Formats

In competitive assays, the amount of p47ING3 present in the sample ismeasured indirectly by measuring the amount of a known, added(exogenous) antigen displaced (competed away) from an anti-antigenantibody by the unknown antigen present in a sample. In one competitiveassay, a known amount of antigen is added to a sample and the sample isthen contacted with an antibody that specifically binds to the antigen.The amount of exogenous antigen bound to the antibody is inverselyproportional to the concentration of antigen present in the sample. In aparticularly preferred embodiment, the antibody is immobilized on asolid substrate. The amount of antigen bound to the antibody may bedetermined either by measuring the amount of antigen present in anantigen/antibody complex, or alternatively by measuring the amount ofremaining uncomplexed protein. The amount of antigen may be detected byproviding a labeled antigen molecule.

A hapten inhibition assay is another preferred competitive assay. Inthis assay the known antigen is immobilized on a solid substrate. Aknown amount of anti-antigen antibody is added to the sample, and thesample is then contacted with the immobilized antigen. The amount ofanti-antigen antibody bound to the known immobilized antigen isinversely proportional to the amount of antigen present in the sample.Again, the amount of immobilized antibody may be detected by detectingeither the immobilized fraction of antibody or the fraction of theantibody that remains in solution. Detection may be direct where theantibody is labeled or indirect by the subsequent addition of a labeledmoiety that specifically binds to the antibody as described above.

Cross-reactivity Determinations

Immunoassays in the competitive binding format can also be used forcrossreactivity determinations. For example, p47ING3 proteins can beimmobilized to a solid support. Proteins (e.g., p33ING1 or p33ING2) areadded to the assay that compete for binding of the antisera to theimmobilized antigen. The ability of the added protein to compete forbinding of the antisera to the immobilized protein is compared to theability of antigen to compete with itself. The percent cross-reactivityfor the above proteins is calculated, using standard calculations. Thoseantisera with less than 10% crossreactivity with the added proteins areselected and pooled. The cross-reacting antibodies are optionallyremoved from the pooled antisera by immunoabsorption with the addedproteins.

The immunoabsorbed and pooled antisera are then used in a competitivebinding immunoassay as described above to compare a second proteinthought to be perhaps an allele, interspecies homologs, or polymorphicvariant of p47ING3, to the immunogen protein. In order to make thiscomparison, the two proteins are each assayed at a wide range ofconcentrations and the amount of each protein required to inhibit 50% ofthe binding of the antisera to the immobilized protein is determined. Ifthe amount of the second protein required to inhibit 50% of binding isless than 10 times the amount of the first protein that is required toinhibit 50% of binding, then the second protein is said to specificallybind to the polyclonal antibodies generated to the immunogen of choice.

Other Assay Formats

Western blot (immunoblot) analysis is used to detect and quantify thepresence of p47ING3 in the sample. The technique generally comprisesseparating sample proteins by gel electrophoresis on the basis ofmolecular weight, transferring the separated proteins to a suitablesolid support, (such as a nitrocellulose filter, a nylon filter, orderivatized nylon filter), and incubating the sample with the antibodiesthat specifically bind p47ING3. The anti-antigen antibodies specificallybind to the antigen on the solid support. These antibodies may bedirectly labeled or alternatively may be subsequently detected usinglabeled antibodies (e.g., labeled sheep anti-mouse antibodies) thatspecifically bind to the anti-antigen antibodies.

Other assay formats include liposome immunoassays (LIA), which useliposomes designed to bind specific molecules (e.g., antibodies) andrelease encapsulated reagents or markers. The released chemicals arethen detected according to standard techniques (see Monroe et al., Amer.Clin. Prod. Rev. 5:34-41 (1986)).

Reduction of Non-specific Binding

One of skill in the art will appreciate that it is often desirable tominimize non-specific binding in immunoassays. Particularly, where theassay involves an antigen or antibody immobilized on a solid substrateit is desirable to minimize the amount of non-specific binding to thesubstrate. Means of reducing such non-specific binding are well known tothose of skill in the art. Typically, this technique involves coatingthe substrate with a proteinaceous composition. In particular, proteincompositions such as bovine serum albumin (BSA), nonfat powdered milk,and gelatin are widely used with powdered milk being most preferred.

Labels

The particular label or detectable group used in the assay is not acritical aspect of the invention, as long as it does not significantlyinterfere with the specific binding of the antibody used in the assay.The detectable group can be any material having a detectable physical orchemical property. Such detectable labels have been well-developed inthe field of immunoassays and, in general, most any label useful in suchmethods can be applied to the present invention. Thus, a label is anycomposition detectable by spectroscopic, photochemical, biochemical,immunochemical, electrical, optical or chemical means. Useful labels inthe present invention include magnetic beads (e.g., DYNABEADS™),fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red,rhodamine, and the like), radiolabels (e.g., ³H, ¹²⁵I, ³⁵S, ¹⁴C, or³²P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase andothers commonly used in an ELISA), and colorimetric labels such ascolloidal gold or colored glass or plastic beads (e.g., polystyrene,polypropylene, latex, etc.).

The label may be coupled directly or indirectly to the desired componentof the assay according to methods well known in the art. As indicatedabove, a wide variety of labels may be used, with the choice of labeldepending on sensitivity required, ease of conjugation with thecompound, stability requirements, available instrumentation, anddisposal provisions.

Non-radioactive labels are often attached by indirect means. Generally,a ligand molecule (e.g., biotin) is covalently bound to the molecule.The ligand then binds to another molecules (e.g., streptavidin)molecule, which is either inherently detectable or covalently bound to asignal system, such as a detectable enzyme, a fluorescent compound, or achemiluminescent compound. The ligands and their targets can be used inany suitable combination with antibodies that recognize a specificprotein, or secondary antibodies that recognize antibodies to thespecific protein.

The molecules can also be conjugated directly to signal generatingcompounds, e.g., by conjugation with an enzyme or fluorophore. Enzymesof interest as labels will primarily be hydrolases, particularlyphosphatases, esterases and glycosidases, or oxidotases, particularlyperoxidases. Fluorescent compounds include fluorescein and itsderivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc.Chemiluminescent compounds include luciferin, and2,3-dihydrophthalazinediones, e.g., luminol. For a review of variouslabeling or signal producing systems that may be used, see U.S. Pat. No.4,391,904.

Means of detecting labels are well known to those of skill in the art.Thus, for example, where the label is a radioactive label, means fordetection include a scintillation counter or photographic film as inautoradiography. Where the label is a fluorescent label, it may bedetected by exciting the fluorochrome with the appropriate wavelength oflight and detecting the resulting fluorescence. The fluorescence may bedetected visually, by means of photographic film, by the use ofelectronic detectors such as charge coupled devices (CCDs) orphotomultipliers and the like. Similarly, enzymatic labels may bedetected by providing the appropriate substrates for the enzyme anddetecting the resulting reaction product. Finally simple colorimetriclabels may be detected simply by observing the color associated with thelabel. Thus, in various dipstick assays, conjugated gold often appearspink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. Forinstance, agglutination assays can be used to detect the presence of thetarget antibodies. In this case, antigen-coated particles areagglutinated by samples comprising the target antibodies. In thisformat, none of the components need be labeled and the presence of thetarget antibody is detected by simple visual inspection.

VI. Assays for Measuring Changes in p47ING3 Regulated Cell Growth

p47ING3 and its alleles, interspecies homologs, and polymorphic variantsparticipate in regulation of cell proliferation and tumor suppression.Therefore, expression of p47ING3 and its alleles, interspecies homologs,and polymorphic variants in host cells would inhibit cell proliferationand suppress tumor formation. On the other hand, expression of p47ING3mutants in a cell would lead to abnormal cell proliferation and loss oftumor suppressor phenotypes. Finally, compounds that activate or inhibitp47ING3 would indirectly affect regulation of cellular proliferation andtumor suppression. Any of these changes in cell growth can be assessedby using a variety of in vitro and in vivo assays, e.g., ability to growon soft agar, changes in contact inhibition and density limitation ofgrowth, changes in growth factor or serum dependence, changes in thelevel of tumor specific markers, changes in invasiveness into Matrigel,changes in tumor growth in vivo, such as in transgenic mice, etc.Furthermore, these assays can be to screen for activators, inhibitors,and modulators of p47ING3. Such activators, inhibitors, and modulatorsof p47ING3 can then be used to modulate p47ING3 expression in tumorcells or abnormal proliferative cells.

A. Assays for Changes in Cell Growth by Expression of p47ING3 Constructs

The following are assays that can be used to identify p47ING3 constructswhich are capable of regulating cell proliferation and tumorsuppression. The phrase “p47ING3 constructs” can refer to any of p47ING3and its alleles, interspecies homologs, polymorphic variants andmutants. Functional p47ING3 constructs identified by the followingassays can then be used in gene therapy to inhibit abnormal cellularproliferation and transformation.

Soft Agar Growth or Colony Formation in Suspension

Normal cells require a solid substrate to attach and grow. When thecells are transformed, they lose this phenotype and grow detached fromthe substrate. For example, transformed cells can grow in stirredsuspension culture or suspended in semi-solid media, such as semi-solidor soft agar. The transformed cells, when transfected with tumorsuppressor genes, regenerate normal phenotype and require a solidsubstrate to attach and grow.

Soft agar growth or colony formation in suspension assays can be used toidentify p47ING3 constructs, which when expressed in host cells, inhibitabnormal cellular proliferation and transformation. Typically,transformed host cells (e.g., cells that grow on soft agar) are used inthis assay. Expression of a tumor suppressor gene in these transformedhost cells would reduce or eliminate the host cells' ability to grow instirred suspension culture or suspended in semi-solid media, such assemi-solid or soft. This is because the host cells would regenerateanchorage dependence of normal cells, and therefore require a solidsubstrate to grow. Therefore, this assay can be used to identify p47ING3constructs which function as a tumor suppressor. Once identified, suchp47ING3 constructs can be used in gene therapy to inhibit abnormalcellular proliferation and transformation.

Techniques for soft agar growth or colony formation in suspension assaysare described in Freshney, Culture of Animal Cells a Manual of BasicTechnique, 3^(rd) ed., Wiley-Liss, New York (1994), herein incorporatedby reference. See also, the methods section of Garkavtsev et al. (1996),supra, herein incorporated by reference.

Contact Inhibition and Density Limitation of Growth

Normal cells typically grow in a flat and organized pattern in a petridish until they touch other cells. When the cells touch one another,they are contact inhibited and stop growing. When cells are transformed,however, the cells are not contact inhibited and continue to grow tohigh densities in disorganized foci. Thus, the transformed cells grow toa higher saturation density than normal cells. This can be detectedmorphologically by the formation of a disoriented monolayer of cells orrounded cells in foci within the regular pattern of normal surroundingcells. Alternatively, labeling index with [³H]-thymidine at saturationdensity can be used to measure density limitation of growth. SeeFreshney (1994), supra. The transformed cells, when transfected withtumor suppressor genes, regenerate a normal phenotype and become contactinhibited and would grow to a lower density.

Contact inhibition and density limitation of growth assays can be usedto identify p47ING3 constructs which are capable of inhibiting abnormalproliferation and transformation in host cells. Typically, transformedhost cells (e.g., cells that are not contact inhibited) are used in thisassay. Expression of a tumor suppressor gene in these transformed hostcells would result in cells which are contact inhibited and grow to alower saturation density than the transformed cells. Therefore, thisassay can be used to identify p47ING3 constructs which function as atumor suppressor. Once identified, such p47ING3 constructs can be usedin gene therapy to inhibit abnormal cellular proliferation andtransformation.

In this assay, labeling index with [³H]-thymidine at saturation densityis a preferred method of measuring density limitation of growth.Transformed host cells are transfected with a p47ING3 construct and aregrown for 24 hours at saturation density in non-limiting mediumconditions. The percentage of cells labeling with [³H]-thymidine isdetermined autoradiographically. See, Freshney (1994), supra. The hostcells expressing a functional p47ING3 construct would give arise to alower labeling index compared to control (e.g., transformed host cellstransfected with a vector lacking an insert).

Growth Factor or Serum Dependence

Growth factor or serum dependence can be used as an assay to identifyfunctional p47ING3 constructs. Transformed cells have a lower serumdependence than their normal counterparts (see, e.g., Temin, J. Natl.Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879(1970)); Freshney, supra. This is in part due to release of variousgrowth factors by the transformed cells. When a tumor suppressor gene istransfected and expressed in these transformed cells, the cells wouldreacquire serum dependence and would release growth factors at a lowerlevel. Therefore, this assay can be used to identify p47ING3 constructswhich function as a tumor suppressor. Growth factor or serum dependenceof transformed host cells which are transfected with a p47ING3 constructcan be compared with that of control (e.g., transformed host cells whichare transfected with a vector without insert). Host cells expressing afunctional p47ING3 would exhibit an increase in growth factor and serumdependence compared to control.

Tumor Specific Markers Levels

Tumor cells release an increased amount of certain factors (hereinafter“tumor specific markers”) than their normal counterparts. For example,plasminogen activator (PA) is released from human glioma at a higherlevel than from normal brain cells (see, e.g., Gullino, Angiogenesis,tumor vascularization, and potential interference with tumor growth. InMihich (ed.): “Biological Responses in Cancer.” New York, AcademicPress, pp. 178-184 (1985)). Similarly, Tumor angiogenesis factor (TAF)is released at a higher level in tumor cells than their normalcounterparts. See, e.g., Folkman, Angiogenesis and cancer, Sem CancerBiol.(1992)).

Tumor specific markers can be assayed for to identify p47ING3constructs, which when expressed, decrease the level of release of thesemarkers from host cells. Typically, transformed or tumorigenic hostcells are used. Expression of a tumor suppressor gene in these hostcells would reduce or eliminate the release of tumor specific markersfrom these cells. Therefore, this assay can be used to identify p47ING3constructs which function as a tumor suppressor.

Various techniques which measure the release of these factors aredescribed in Freshney (1994), supra. Also, see, Unkless et al., J. Biol.Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem.251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305-312 (1980);Gulino, Angiogenesis, tumor vascularization, and potential interferencewith tumor growth. In Mihich, E. (ed): “Biological Responses in Cancer.”New York, Plenum (1985); Freshney Anticancer Res. 5:111-130 (1985).

Invasiveness into Matrigel

The degree of invasiveness into Matrigel or some other extracellularmatrix constituent can be used as an assay to identify p47ING3constructs which are capable of inhibiting abnormal cell proliferationand tumor growth. Tumor cells exhibit a good correlation betweenmalignancy and invasiveness of cells into Matrigel or some otherextracellular matrix constituent. In this assay, tumorigenic cells aretypically used as host cells. Expression of a tumor suppressor gene inthese host cells would decrease invasiveness of the host cells.Therefore, functional p47ING3 constructs can be identified by measuringchanges in the level of invasiveness between the host cells before andafter the introduction of p47ING3 constructs. If a p47ING3 constructfunctions as a tumor suppressor, its expression in tumorigenic hostcells would decrease invasiveness.

Techniques described in Freshney (1994), supra, can be used. Briefly,the level of invasion of host cells can be measured by using filterscoated with Matrigel or some other extracellular matrix constituent.Penetration into the gel, or through to the distal side of the filter,is rated as invasiveness, and rated histologically by number of cellsand distance moved, or by prelabeling the cells with ¹²⁵I and countingthe radioactivity on the distal side of the filter or bottom of thedish. See, e.g., Freshney (1984), supra.

Cell Cycle Analysis

Cell cycle analysis can be used to determine if a gene can suppress thegrowth of a cell. Briefly, cells are transfected with an expressioncassette containing the gene of interest. If the gene encodes a proteinthat can arrest or inhibit cell division then the gene is suppressingthe growth of the cells. Cell division, or mitosis, consists of severalsuccessive phases in a eukaryotic cell (Molecular Biology of the Cell,3d edition (Alberts et al., eds., 1994)). These phases, in order, areknown as G₁, S, G₂ and M. DNA replication takes place during the Sphase. The mitotic phase, where nuclear division takes place, is termedthe M phase. The G₁ phase is the time between the M phase and the Sphase. G₂ is the time between the end of the S phase and the beginningof the M phase. Cells can pause in G₁ and enter a specialized restingstate known as G₀. Cells can remain in G₀ for days to years, until theyresume the cell-cycle. Methods of analyzing the phase of the cell-cycleare known in the art and include methods that involve determining if thecell is replicating DNA (e.g., [H³]-thymidine incorporation assays).Alternatively, methods are known in the art for measuring the DNAcontent of a cell, which doubles during the S phase. FACS (Fluorescentactivated cell sorting) analysis can be used to determine the percentageof a population of cells in a particular stage of the cell-cycle (seegenerally, Alberts et al., supra; see also van den Heuvel and Harlow,(1993) Science 262: 2050-2054). The cells are incubated with a dye thatfluoresces (e.g., propidium iodide) when it binds to the DNA of thecell. Thus, the amount of fluorescence of a cell is proportional to theDNA content of a cell. Cells that are in G₁ or G₀ (G₁/G₀) have anunreplicated complement of DNA and are deemed to have 1 arbitrary unitof DNA in the cell. Those cells that have fully replicated, i.e., havedoubled their DNA content, are deemed to have 2 arbitrary units of DNAin the cell and are in the G₂ or M phase (G₂/M) of the cell cycle. Cellswith an amount of DNA that is between 1 and 2 arbitrary units are in Sphase.

The effect of a protein of interest on the cell cycle can be determinedby transfecting cells with DNA encoding the protein of interest andanalyzing its effect on the cell cycle through flow cytometry in a FACS.The cells are co-transfected with a vector encoding a marker to identifyand analyze those cells that are actually transfected. Such markers caninclude the B cell surface marker CD20 (van de Heuvel and Harlow, supra)or a farnesylated green fluorescent protein (GFP-F) (Jiang and Hunter,(1998) Biotechniques, 24(3): 349-50, 352, 354).

For example, the percentage of cells in a particular stage of thecell-cycle can be determined using the method of Jiang and Hunter,(1998) supra. Briefly, a population of cells are transfected with avector encoding p47ING3 and a vector encoding a green fluorescentprotein (GFP) with a farnesylation signal sequence from c-Ha-Ras. Thefarnesylation signal sequence is farnesylated in the cell, which targetsthe GFP molecule to the plasma membrane. Vectors encoding farnesylatedGFP are commercially available (e.g., pEGFP-F from Clontech).

After transfection, the cells are suspended in buffer containing the DNAintercalator propidium iodide. Propidium iodide will fluoresce when itis bound to DNA. Thus, the amount of fluorescence observed frompropidium iodide in a FACS flow cytometer is an indication of the DNAcontent of a cell. The percentages of cells in each cell cycle can becalculated using computer programs, e.g., the ModFit program(Becton-Dickinson). The cell cycle stage of the cell was analyzed aftergating cells by GFP fluorescence using FACscan. If the gene encodes atumor suppressor, the percentage of cells that enter S phase would bedecreased, as the cells are arrested in the G₀/G₁ phase. Therefore, thepercentage of cells that are G₀/G₁ phase would be increased.

Tumor Growth in vivo

Effects of p47ING3 on cell growth can be tested in transgenic orimmune-suppressed mice. Knock-out transgenic mice can be made, in whichthe endogenous p47ING3 gene is disrupted. Such knock-out mice can beused to study effects of p47ING3, e.g., as a cancer model, as a means ofassaying in vivo for compounds that modulate p47ING3, and to test theeffects of restoring a wildtype p47ING3 to a knock-out mice.

Knock-out transgenic mice can be made by insertion of a marker gene orother heterolgous gene into the endogenous p47ING3 gene site in themouse genome via homologous recombination. Such mice can also be made bysubstituting the endogenous p47ING3 with a mutated version of p47ING3,or by mutating the endogenous p47ING3, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells.Cells containing the newly engineered genetic lesion are injected into ahost mouse embryo, which is re-implanted into a recipient female. Someof these embryos develop into chimeric mice that possess germ cellspartially derived from the mutant cell line. Therefore, by breeding thechimeric mice it is possible to obtain a new line of mice containing theintroduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288(1989)). Chimeric targeted mice can be derived according to Hogan etal., Manipulating the Mouse Embryo: A Laboratory Manual, Cold SpringHarbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells:A Practical Approach, Robertson, ed., IRL Press, Washington, D.C.,(1987).

These knock-out mice can be used as hosts to test the effects of variousp47ING3 constructs on cell growth. These transgenic mice with theendogenous p47ING3 gene knocked out would develop abnormal cellproliferation and tumor growth. They can be used as hosts to test theeffects of various p47ING3 constructs on cell growth. For example,introduction of wildtype p47ING3 into these knock-out mice would inhibitabnormal cellular proliferation and suppress tumor growth.

Alternatively, various immune-suppressed or immune-deficient hostanimals can be used. For example, genetically athymic “nude” mouse (see,e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCIDmouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradleyet al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52(1980)) can be used as a host. Transplantable tumor cells (typicallyabout 10⁶ cells) injected into isogenic hosts will produce invasivetumors in a high proportions of cases, while normal cells of similarorigin will not. In hosts which developed invasive tumors, cellsexpressing a p47ING3 construct are injected subcutaneously. After asuitable length of time, preferably 4-8 weeks, tumor growth is measured(e.g., by volume or by its two largest dimensions) and compared to thecontrol. Tumors that have statistically significant reduction (using,e.g., Student's T test) are said to have inhibited growth. Usingreduction of tumor size as an assay, functional p47ING3 constructs whichare capable of inhibiting abnormal cell proliferation can be identified.This model can also be used to identify mutant versions of p47ING3.

B. Assays for Compounds that Modulate p47ING3

p47ING3 and its alleles, interspecies homologs, and polymorphic variantsparticipate in regulation of cell proliferation and tumor suppression.Mutations in these genes, including null or missense mutations, cancause abnormal cell proliferation and tumor growth. The activity ofp47ING3 polypeptides (wildtype or mutants) can be assessed using avariety of in vitro and in vivo assays measuring various parameters,e.g., cell growth on soft agar, contact inhibition and densitylimitation of growth, growth factor or serum dependence, tumor specificmarkers levels, invasiveness into Matrigel, tumor growth in vivo,transgenic mice, p47ING3 protein or mRNA levels, transcriptionalactivation or repression of a reporter gene, and the like. Such assayscan also be used to screen for activators, inhibitors, and modulators ofwildtype and mutant p47ING3. Such activators, inhibitors, and modulatorsare useful in inhibiting tumor growth and modulating cell proliferation.Compounds identified using the assays of the invention are useful astherapeutics for treatment of cancer and other diseases involvingcellular hyperproliferation.

Biologically active or inactivated p47ING3 polypeptides, eitherrecombinants or naturally occurring, are used to screen activators,inhibitors, or modulators of tumor suppression and cell proliferation.The p47ING3 polypeptides can be recombinantly expressed in a cell,naturally expressed in a cell, recombinantly or naturally expressed incells transplanted into an animal, or recombinantly or naturallyexpressed in a transgenic animal. Modulation is tested using one of thein vitro or in vivo assays described in herein in part A.

Cells that have wildtype p47ING3 are used in the assays of theinvention, both in vitro and in vivo. Preferably, human cells are used.Cell lines can also be created or isolated from tumors that have mutantp47ING3. Optionally, the cells can be transfected with an exogenousp47ING3 gene operably linked to a constitutive promoter, to providehigher levels of p47ING3 expression. Alternatively, endogenous p47ING3levels can be examined. The cells can be treated to induce p47ING3expression. The cells can be immobilized, be in solution, be injectedinto an animal, or be naturally occurring in a transgenic ornon-transgenic animal.

Samples or assays that are treated with a test compound whichpotentially activates, inhibits, or modulates p47ING3 are compared tocontrol samples that are not treated with the test compound, to examinethe extent of modulation. Generally, the compounds to be tested arepresent in the range from 0.1 nM to 10 mM. Control samples (untreatedwith activators, inhibitors, or modulators) are assigned relativep47ING3 activity value of 100%. Inhibition of p47ING3 is achieved whenthe p47ING3 activity value relative to the control is about 90% (e.g.,10% less than the control), preferably 50%, more preferably 25%.Activation of p47ING3 is achieved when the p47ING3 activity valuerelative to the control is 110% (e.g., 10% more than the control), morepreferably 150%, more preferably 200% higher.

The effects of the test compounds upon the function of the p47ING3polypeptides can be measured by examining any of the parametersdescribed above. For example, parameters such as ability to grow on softagar, contact inhibition and density limitation of growth, growth factoror serum dependence, tumor specific markers levels, invasiveness intoMatrigel, tumor growth in vivo, transgenic mice and the like, can bemeasured. Furthermore, the effects of the test compounds on p47ING3protein or mRNA levels, transcriptional activation or repression of areporter gene can be measured. In each assay, cells expressing p47ING3are contacted with a test compound and incubated for a suitable amountof time, e.g., from 0.5 to 48 hours. Then, parameters such as thosedescribed above are compared to those produced by control cellsuntreated with the test compound.

In one embodiment, the effect of test compounds upon the function ofp47ING3 can be determined by comparing the level of p47ING3 protein ormRNA in treated samples and control samples. The level of p47ING3protein is measured using immunoassays such as western blotting, ELISAand the like with a p47ING3 specific antibody. For measurement of mRNA,amplification, e.g., using PCR, LCR, or hybridization assays, e.g.,northern hybridization, RNase protection, dot blotting, are preferred.The level of protein or mRNA is detected using directly or indirectlylabeled detection agents, e.g., fluorescently or radioactively labelednucleic acids, radioactively or enzymatically labeled antibodies, andthe like, as described herein.

Alternatively, a reporter gene system can be devised using the p47ING3promoter operably linked to a reporter gene such as luciferase, greenfluorescent protein, CAT, or β-gal. After treatment with a potentialp47ING3 modulator, the amount of reporter gene transcription,translation, or activity is measured according to standard techniquesknown to those of skill in the art.

In another embodiment, the effects of test compounds on p47ING3 activityis performed in vivo. In this assay, cultured cells that are expressinga wildtype or mutant p47ING3 (e.g., a null or missense mutation) areinjected subcutaneously into an immune compromised mouse such as anathymic mouse, an irradiated mouse, or a SCID mouse. The p47ING3modulators are administered to the mouse, e.g., a chemical ligandlibrary. After a suitable length of time, preferably 4-8 weeks, tumorgrowth is measured, e.g., by volume or by its two largest dimensions,and compared to the control. Tumors that have statistically significantreduction (using, e.g., Student's T test) are said to have inhibitedgrowth. Alternatively, the extent of tumor neovascularization can alsobe measured. Immunoassays using endothelial cell specific antibodies areused to stain for vascularization of the tumor and the number of vesselsin the tumor. Tumors that have a statistically significant reduction inthe number of vessels (using, e.g., Student's T test) are said to haveinhibited neovascularization.

Alternatively, transgenic mice with the endogenous p47ING3 gene knockedout can be used in an assay to screen for compounds which modulate thep47ING3 activity. As described in part A, knock-out transgenic mice canbe made, in which the endogenous p47ING3 gene is disrupted, e.g., byreplacing it with a marker gene. A transgenic mouse that is heterozygousor homozygous for integrated transgenes that have functionally disruptedthe endogenous p47ING3 gene can be used as a sensitive in vivo screeningassay for p47ING3 ligands and modulators of p47ING3 activity.

C. Modulators

The compounds tested as modulators of p47ING3 can be any small chemicalcompound, or a biological entity, such as a protein, sugar, nucleic acidor lipid. Alternatively, modulators can be genetically altered versionsof p47ING3. For example, an antisense construct of p47ING3 can be usedas a modulator.

Typically, test compounds will be small chemical molecules and peptides.Essentially any chemical compound can be used as a potential modulatoror ligand in the assays of the invention, although most often compoundscan be dissolved in aqueous or organic (especially DMSO-based) solutionsare used. The assays are designed to screen large chemical libraries byautomating the assay steps and providing compounds from any convenientsource to assays, which are typically run in parallel (e.g., inmicrotiter formats on microtiter plates in robotic assays). It will beappreciated that there are many suppliers of chemical compounds,including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.),Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika(Buchs Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involveproviding a combinatorial chemical or peptide library containing a largenumber of potential therapeutic compounds (potential modulator or ligandcompounds). Such “combinatorial chemical libraries” or “ligandlibraries” are then screened in one or more assays, as described herein,to identify those library members (particular chemical species orsubclasses) that display a desired characteristic activity. Thecompounds thus identified can serve as conventional “lead compounds” orcan themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemicalcompounds generated by either chemical synthesis or biologicalsynthesis, by combining a number of chemical “building blocks” such asreagents. For example, a linear combinatorial chemical library such as apolypeptide library is formed by combining a set of chemical buildingblocks (amino acids) in every possible way for a given compound length(i.e., the number of amino acids in a polypeptide compound). Millions ofchemical compounds can be synthesized through such combinatorial mixingof chemical building blocks.

Preparation and screening of combinatorial chemical libraries is wellknown to those of skill in the art. Such combinatorial chemicallibraries include, but are not limited to, peptide libraries (see, e.g.,U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493(1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistriesfor generating chemical diversity libraries can also be used. Suchchemistries include, but are not limited to: peptoids (e.g., PCTPublication No. WO 91/19735), encoded peptides (e.g., PCT PublicationNo. WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomerssuch as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc.Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides(Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidalpeptidomimetics with glucose scaffolding (Hirschmann et al., J. Amer.Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of smallcompound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)),oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidylphosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleicacid libraries (see Ausubel et al. supra, Berger and Sambrook, allsupra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No.5,539,083), antibody libraries (see, e.g., Vaughn et al., NatureBiotechnology, 14(3):309-314 (1996) and PCT/US96/10287), carbohydratelibraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) andU.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g.,benzodiazepines, Baum C&EN, January 18, page 33 (1993); isoprenoids,U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat.No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134;morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S.Pat. No. 5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commerciallyavailable (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, LouisvilleKy., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, FosterCity, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition,numerous combinatorial libraries are themselves commercially available(see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc.,St. Louis, Mo., ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton,Pa., Martek Biosciences, Columbia, Md., etc.).

In one embodiment, the invention provides solid phase based in vitroassays in a high throughput format, where the cell or tissue expressingp47ING3 is attached to a solid phase substrate. In the high throughputassays of the invention, it is possible to screen up to several thousanddifferent modulators or ligands in a single day. In particular, eachwell of a microtiter plate can be used to run a separate assay against aselected potential modulator, or, if concentration or incubation timeeffects are to be observed, every 5-10 wells can test a singlemodulator. Thus, a single standard microtiter plate can assay about 100(e.g., 96) modulators. If 1536 well plates are used, then a single platecan easily assay from about 100-about 1500 different compounds. It ispossible to assay several different plates per day; assay screens for upto about 6,000-20,000 different compounds is possible using theintegrated systems of the invention. More recently, microfluidicapproaches to reagent manipulation have been developed, e.g., by CaliperTechnologies (Palo Alto, Calif.).

D. Computer-based Assays

Yet another assay for compounds that modulate p47ING3 activity involvescomputer assisted drug design, in which a computer system is used togenerate a three-dimensional structure of p47ING3 based on thestructural information encoded by the amino acid sequence. The inputamino acid sequence interacts directly and actively with apreestablished algorithm in a computer program to yield secondary,tertiary, and quaternary structural models of the protein. The models ofthe protein structure are then examined to identify regions of thestructure that have the ability to bind, e.g., ligands. These regionsare then used to identify ligands that bind to the protein.

The three-dimensional structural model of the protein is generated byentering p47ING3 amino acid sequences of at least 10 amino acid residuesor corresponding nucleic acid sequences encoding a p47ING3 polypeptideinto the computer system. The amino acid sequence of the polypeptide orthe nucleic acid encoding the polypeptide is selected from the groupconsisting of SEQ ID NO:1 or SEQ ID NO:2, and conservatively modifiedversions thereof. The amino acid sequence represents the primarysequence or subsequence of the protein, which encodes the structuralinformation of the protein. At least 10 residues of the amino acidsequence (or a nucleotide sequence encoding 10 amino acids) are enteredinto the computer system from computer keyboards, computer readablesubstrates that include, but are not limited to, electronic storagemedia (e.g., magnetic diskettes, tapes, cartridges, and chips), opticalmedia (e.g., CD ROM), information distributed by internet sites, and byRAM. The three-dimensional structural model of the protein is thengenerated by the interaction of the amino acid sequence and the computersystem, using software known to those of skill in the art. Thethree-dimensional structural model of the protein can be saved to acomputer readable form and be used for further analysis (e.g.,identifying potential ligand binding regions of the protein andscreening for mutations, alleles and interspecies homologs of the gene).

The amino acid sequence represents a primary structure that encodes theinformation necessary to form the secondary, tertiary and quaternarystructure of the protein of interest. The software looks at certainparameters encoded by the primary sequence to generate the structuralmodel. These parameters are referred to as “energy terms,” and primarilyinclude electrostatic potentials, hydrophobic potentials, solventaccessible surfaces, and hydrogen bonding. Secondary energy termsinclude van der Waals potentials. Biological molecules form thestructures that minimize the energy terms in a cumulative fashion. Thecomputer program is therefore using these terms encoded by the primarystructure or amino acid sequence to create the secondary structuralmodel.

The tertiary structure of the protein encoded by the secondary structureis then formed on the basis of the energy terms of the secondarystructure. The user at this point can enter additional variables such aswhether the protein is membrane bound or soluble, its location in thebody, and its cellular location, e.g., cytoplasmic, surface, or nuclear.These variables along with the energy terms of the secondary structureare used to form the model of the tertiary structure. In modeling thetertiary structure, the computer program matches hydrophobic faces ofsecondary structure with like, and hydrophilic faces of secondarystructure with like.

Once the structure has been generated, potential ligand binding regionsare identified by the computer system. Three-dimensional structures forpotential ligands are generated by entering amino acid or nucleotidesequences or chemical formulas of compounds, as described above. Thethree-dimensional structure of the potential ligand is then compared tothat of the p47ING3 protein to identify ligands that bind to p47ING3.Binding affinity between the protein and ligands is determined usingenergy terms to determine which ligands have an enhanced probability ofbinding to the protein. The results, such as three-dimensionalstructures for potential ligands and binding affinity of ligands, canalso be saved to a computer readable form and can be used for furtheranalysis (e.g., generating a three dimensional model of mutated proteinshaving an altered binding affinity for a ligand).

Computer systems are also used to screen for mutations, polymorphicvariants, alleles and interspecies homologs of p47ING3 genes. Suchmutations can be associated with disease states or genetic traits. Asdescribed above, high density oligonucleotide arrays (GeneChip™) andrelated technology can also be used to screen for mutations, polymorphicvariants, alleles and interspecies homologs. Once the variants areidentified, diagnostic assays can be used to identify patients havingsuch mutated genes. Identification of the mutated p47ING3 genes involvesreceiving input of a first nucleic acid or amino acid sequence encodingselected from the group consisting of SEQ ID NO:2, or SEQ ID NO:1, andconservatively modified versions thereof. The sequence is entered intothe computer system as described above and then saved to a computerreadable form. The first nucleic acid or amino acid sequence is thencompared to a second nucleic acid or amino acid sequence that hassubstantial identity to the first sequence. The second sequence isentered into the computer system in the manner described above. Once thefirst and second sequences are compared, nucleotide or amino aciddifferences between the sequences are identified. Such sequences canrepresent allelic differences in p47ING3 genes, and rotations associatedwith disease states and genetic traits.

VII. Gene Therapy

The present invention provides the nucleic acids of p47ING3 for thetransfection of cells in vitro and in vivo. These nucleic acids can beinserted into any of a number of well known vectors for the transfectionof target cells and organisms as described below. The nucleic acids aretransfected into cells, ex vivo or in vivo, through the interaction ofthe vector and the target cell. The nucleic acids encoding p47ING3,under the control of a promoter, then expresses a p47ING3 of the presentinvention, thereby mitigating the effects of absent, partialinactivation, or abnormal expression of the p47ING3 gene.

Such gene therapy procedures have been used to correct acquired andinherited genetic defects, cancer, and viral infection in a number ofcontexts. The ability to express artificial genes in humans facilitatesthe prevention and/or cure of many important human diseases, includingmany diseases which are not amenable to treatment by other therapies(for a review of gene therapy procedures, see Anderson, Science256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217 (1993); Mitani &Caskey, TIBTECH 11:162-166 (1993); Mulligan, Science 926-932 (1993);Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992);Van Brunt, Biotechnology 6(10):1149-1154 (1998); Vigne, RestorativeNeurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, BritishMedical Bulletin 51(1):31-44 (1995); Haddada et al., in Current Topicsin Microbiology and Immunology (Doerfler & Böhm eds., 1995); and Yu etal., Gene Therapy 1:13-26 (1994)).

Delivery of the gene or genetic material into the cell is the firstcritical step in gene therapy treatment of disease. A large number ofdelivery methods are well known to those of skill in the art.Preferably, the nucleic acids are administered for in vivo or ex vivogene therapy uses. Non-viral vector delivery systems include DNAplasmids, naked nucleic acid, and nucleic acid complexed with a deliveryvehicle such as a liposome. Viral vector delivery systems include DNAand RNA viruses, which have either episomal or integrated genomes afterdelivery to the cell. For a review of gene therapy procedures, seeAnderson, Science 256:808-813 (1992); Nabel & Felgner, TIBTECH11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon,TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt,Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology andNeuroscience 8:35-36 (1995); Kremer & Perricaudet, British MedicalBulletin 51(1):31-44 (1995); Haddada et al., in Current Topics inMicrobiology and Immunology Doerfler and Böhm (eds) (1995); and Yu etal., Gene Therapy 1:13-26 (1994).

Methods of non-viral delivery of nucleic acids include lipofection,microinjection, biolistics, virosomes, liposomes, immunoliposomes,polycation or lipid:nucleic acid conjugates, naked DNA, artificialvirions, and agent-enhanced uptake of DNA. Lipofection is described in,e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) andlipofection reagents are sold commercially (e.g., Transfectam™ andLipofectin™). Cationic and neutral lipids that are suitable forefficient receptor-recognition lipofection of polynucleotides includethose of Felgner, WO 91/17424, WO 91/16024. Delivery can be to cells (exvivo administration) or target tissues (in vivo administration).

The preparation of lipid:nucleic acid complexes, including targetedliposomes such as immunolipid complexes, is well known to one of skillin the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese etal., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem.5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gaoet al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res.52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871,4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

The use of RNA or DNA viral based systems for the delivery of nucleicacids take advantage of highly evolved processes for targeting a virusto specific cells in the body and trafficking the viral payload to thenucleus. Viral vectors can be administered directly to patients (invivo) or they can be used to treat cells in vitro and the modified cellsare administered to patients (ex vivo). Conventional viral based systemsfor the delivery of nucleic acids could include retroviral, lentivirus,adenoviral, adeno-associated and herpes simplex virus vectors for genetransfer. Viral vectors are currently the most efficient and versatilemethod of gene transfer in target cells and tissues. Integration in thehost genome is possible with the retrovirus, lentivirus, andadeno-associated virus gene transfer methods, often resulting in longterm expression of the inserted transgene. Additionally, hightransduction efficiencies have been observed in many different celltypes and target tissues.

The tropism of a retrovirus can be altered by incorporating foreignenvelope proteins, expanding the potential target population of targetcells. Lentiviral vectors are retroviral vector that are able totransduce or infect non-dividing cells and typically produce high viraltiters. Selection of a retroviral gene transfer system would thereforedepend on the target tissue. Retroviral vectors are comprised ofcis-acting long terminal repeats with packaging capacity for up to 6-10kb of foreign sequence. The minimum cis-acting LTRs are sufficient forreplication and packaging of the vectors, which are then used tointegrate the therapeutic gene into the target cell to provide permanenttransgene expression. Widely used retroviral vectors include those basedupon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV),Simian Immuno deficiency virus (SIV), human immuno deficiency virus(HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol.66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992);Sommerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol.63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991);PCT/US94/05700).

In applications where transient expression of the nucleic acid ispreferred, adenoviral based systems are typically used. Adenoviral basedvectors are capable of very high transduction efficiency in many celltypes and do not require cell division. With such vectors, high titerand levels of expression have been obtained. This vector can be producedin large quantities in a relatively simple system. Adeno-associatedvirus (“AAV”) vectors are also used to transduce cells with targetnucleic acids, e.g., in the in vitro production of nucleic acids andpeptides, and for in vivo and ex vivo gene therapy procedures (see,e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368;WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J.Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectorsare described in a number of publications, including U.S. Pat. No.5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985);Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat &Muzyczka, Proc. Natl. Acad. Sci. U.S.A. 81:6466-6470 (1984); andSamulski et al., J. Virol. 63:03822-3828 (1989).

In particular, at least six viral vector approaches are currentlyavailable for gene transfer in clinical trials, with retroviral vectorsby far the most frequently used system. All of these viral vectorsutilize approaches that involve complementation of defective vectors bygenes inserted into helper cell lines to generate the transducing agent.

pLASN and MFG-S are examples are retroviral vectors that have been usedin clinical trials (Dunbar et al., Blood 85:3048-305 (1995); Kohn etal., Nat. Med. 1:1017-102 (1995); Malech et al., Proc. Natl. Acad. Sci.U.S.A. 94:22 12133-12138 (1997)). PA317/pLASN was the first therapeuticvector used in a gene therapy trial. (Blaese et al., Science 270:475-480(1995)). Transduction efficiencies of 50% or greater have been observedfor MFG-S packaged vectors. (Ellem et al., Immunol Immunother.44(1):10-20 (1997); Dranoff et al., Hum. Gene Ther. 1:111-2 (1997).

Recombinant adeno-associated virus vectors (rAAV) are a promisingalternative gene delivery systems based on the defective andnonpathogenic parvovirus adeno-associated type 2 virus. All vectors arederived from a plasmid that retains only the AAV 145 bp invertedterminal repeats flanking the transgene expression cassette. Efficientgene transfer and stable transgene delivery due to integration into thegenomes of the transduced cell are key features for this vector system.(Wagner et al., Lancet 351:9117 1702-3 (1998), Kearns et al., Gene Ther.9:748-55 (1996)).

Replication-deficient recombinant adenoviral vectors (Ad) arepredominantly used transient expression gene therapy, because they canbe produced at high titer and they readily infect a number of differentcell types. Most adenovirus vectors are engineered such that a transgenereplaces the Ad E1a, E1b, and E3 genes; subsequently the replicationdefector vector is propagated in human 293 cells that supply deletedgene function in trans. Ad vectors can transduce multiply types oftissues in vivo, including nondividing, differentiated cells such asthose found in the liver, kidney and muscle system tissues. ConventionalAd vectors have a large carrying capacity. An example of the use of anAd vector in a clinical trial involved polynucleotide therapy forantitumor immunization with intramuscular injection (Sterman et al.,Hum. Gene Ther. 7:1083-9 (1998)). Additional examples of the use ofadenovirus vectors for gene transfer in clinical trials includeRosenecker et al., Infection 24:1 5-10 (1996); Sterman et al., Hum. GeneTher. 9:7 1083-1089 (1998); Welsh et al., Hum. Gene Ther. 2:205-18(1995); Alvarez et al., Hum. Gene Ther. 5:597-613 (1997); Topf et al.,Gene Ther. 5:507-513 (1998); Sterman et al., Hum. Gene Ther. 7:1083-1089(1998).

Packaging cells are used to form virus particles that are capable ofinfecting a host cell. Such cells include 293 cells, which packageadenovirus, and ψ2 cells or PA317 cells, which package retrovirus. Viralvectors used in gene therapy are usually generated by producer cell linethat packages a nucleic acid vector into a viral particle. The vectorstypically contain the minimal viral sequences required for packaging andsubsequent integration into a host, other viral sequences being replacedby an expression cassette for the protein to be expressed. The missingviral functions are supplied in trans by the packaging cell line. Forexample, AAV vectors used in gene therapy typically only possess ITRsequences from the AAV genome which are required for packaging andintegration into the host genome. Viral DNA is packaged in a cell line,which contains a helper plasmid encoding the other AAV genes, namely repand cap, but lacking ITR sequences. The cell line is also infected withadenovirus as a helper. The helper virus promotes replication of the AAVvector and expression of AAV genes from the helper plasmid. The helperplasmid is not packaged in significant amounts due to a lack of ITRsequences. Contamination with adenovirus can be reduced by, e.g., heattreatment to which adenovirus is more sensitive than AAV.

In many gene therapy applications, it is desirable that the gene therapyvector be delivered with a high degree of specificity to a particulartissue type. A viral vector is typically modified to have specificityfor a given cell type by expressing a ligand as a fusion protein with aviral coat protein on the viruses outer surface. The ligand is chosen tohave affinity for a receptor known to be present on the cell type ofinterest. For example, Han et al., Proc. Natl. Acad. Sci. U.S.A.92:9747-9751 (1995), reported that Moloney murine leukemia virus can bemodified to express human heregulin fused to gp70, and the recombinantvirus infects certain human breast cancer cells expressing humanepidermal growth factor receptor. This principle can be extended toother pairs of virus expressing a ligand fusion protein and target cellexpressing a receptor. For example, filamentous phage can be engineeredto display antibody fragments (e.g., Fab or Fv) having specific bindingaffinity for virtually any chosen cellular receptor. Although the abovedescription applies primarily to viral vectors, the same principles canbe applied to nonviral vectors. Such vectors can be engineered tocontain specific uptake sequences thought to favor uptake by specifictarget cells.

Gene therapy vectors can be delivered in vivo by administration to anindividual patient, typically by systemic administration (e.g.,intravenous, intraperitoneal, intramuscular, subdermal, or intracranialinfusion) or topical application, as described below. Alternatively,vectors can be delivered to cells ex vivo, such as cells explanted froman individual patient (e.g., lymphocytes, bone marrow aspirates, tissuebiopsy) or universal donor hematopoietic stem cells, followed byreimplantation of the cells into a patient, usually after selection forcells which have incorporated the vector.

Ex vivo cell transfection for diagnostics, research, or for gene therapy(e.g., via re-infusion of the transfected cells into the host organism)is well known to those of skill in the art. In a preferred embodiment,cells are isolated from the subject organism, transfected with a nucleicacid (gene or cDNA), and re-infused back into the subject organism(e.g., patient). Various cell types suitable for ex vivo transfectionare well known to those of skill in the art (see, e.g., Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique (3rd ed. 1994)) andthe references cited therein for a discussion of how to isolate andculture cells from patients).

In one embodiment, stem cells are used in ex vivo procedures for celltransfection and gene therapy. The advantage to using stem cells is thatthey can be differentiated into other cell types in vitro, or can beintroduced into a mammal (such as the donor of the cells) where theywill engraft in the bone marrow. Methods for differentiating CD34+ cellsin vitro into clinically important immune cell types using cytokinessuch a GM-CSF, IFN-γ and TNF-α are known (see Inaba et al., J. Exp. Med.176:1693-1702 (1992)).

Stem cells are isolated for transduction and differentiation using knownmethods. For example, stem cells are isolated from bone marrow cells bypanning the bone marrow cells with antibodies which bind unwanted cells,such as CD4+ and CD8+ (T cells), CD45+ (panB cells), GR-1(granulocytes), and Iad (differentiated antigen presenting cells) (seeInaba et al., J. Exp. Med. 176:1693-1702 (1992)).

Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containingtherapeutic nucleic acids can be also administered directly to theorganism for transduction of cells in vivo. Alternatively, naked DNA canbe administered.

Administration is by any of the routes normally used for introducing amolecule into ultimate contact with blood or tissue cells, as describedbelow. The nucleic acids are administered in any suitable manner,preferably with pharmaceutically acceptable carriers. Suitable methodsof administering such nucleic acids are available and well known tothose of skill in the art, and, although more than one route can be usedto administer a particular composition, a particular route can oftenprovide a more immediate and more effective reaction than another route(see Proc. Natl. Acad. Sci. U.S.A. 81:6466-6470 (1984); and Samulski etal., J. Virol. 63:03822-3828 (1989)). In particular, at least six viralvector approaches are currently available for gene transfer in clinicaltrials, with retroviral vectors by far the most frequently used system.All of these viral vectors utilize approaches that involvecomplementation of defective vectors by genes inserted into helper celllines to generate the transducing agent.

VIII. Pharmaceutical Compositions and Administration

p47ING3 nucleic acid, protein, and modulators of p47ING3 can beadministered directly to the patient for inhibition of cancer, tumor, orprecancer cells in vivo. Administration is by any of the routes normallyused for introducing a compound into ultimate contact with the tissue tobe treated. The compounds are administered in any suitable manner,preferably with pharmaceutically acceptable carriers. Suitable methodsof administering such compounds are available and well known to those ofskill in the art, and, although more than one route can be used toadminister a particular composition, a particular route can oftenprovide a more immediate and more effective reaction than another route.

Pharmaceutically acceptable carriers are determined in part by theparticular composition being administered, as well as by the particularmethod used to administer the composition. Accordingly, there is a widevariety of suitable formulations of pharmaceutical compositions of thepresent invention (see, e.g., Remington's Pharmaceutical Sciences,17^(th) ed. 1985)).

The compounds (nucleic acids, proteins, and modulators), alone or incombination with other suitable components, can be made into aerosolformulations (i.e., they can be “nebulized”) to be administered viainhalation. Aerosol formulations can be placed into pressurizedacceptable propellants, such as dichlorodifluoromethane, propane,nitrogen, and the like.

Formulations suitable for parenteral administration, such as, forexample, by intravenous, intramuscular, intradermal, and subcutaneousroutes, include aqueous and non-aqueous, isotonic sterile injectionsolutions, which can contain antioxidants, buffers, bacteriostats, andsolutes that render the formulation isotonic with the blood of theintended recipient, and aqueous and non-aqueous sterile suspensions thatcan include suspending agents, solubilizers, thickening agents,stabilizers, and preservatives. In the practice of this invention,compositions can be administered, for example, by intravenous infusion,orally, topically, intraperitoneally, intravesically or intrathecally.The formulations of compounds can be presented in unit-dose ormulti-dose sealed containers, such as ampules and vials. Injectionsolutions and suspensions can be prepared from sterile powders,granules, and tablets of the kind previously described.

The dose administered to a patient, in the context of the presentinvention should be sufficient to effect a beneficial therapeuticresponse in the patient over time. The dose will be determined by theefficacy of the particular compound employed and the condition of thepatient, as well as the body weight or surface area of the patient to betreated. The size of the dose also will be determined by the existence,nature, and extent of any adverse side-effects that accompany theadministration of a particular compound or vector in a particularpatient.

In determining the effective amount of the modulator to be administeredin the treatment or prophylaxis of cancer, the physician evaluatescirculating plasma levels of the modulator, modulator toxicities,progression of the disease, and the production of anti-modulatorantibodies. In general, the dose equivalent of a modulator is from about1 ng/kg to 10 mg/kg for a typical patient. Administration of compoundsis well known to those of skill in the art (see, e.g., Bansinath et al.,Neurochem Res. 18:1063-1066 (1993); Iwasaki et al., Jpn. J. Cancer Res.88:861-866 (1997); Tabrizi-Rad et al., Br. J. Pharmacol.111:394-396(1994)).

For administration, modulators of the present invention can beadministered at a rate determined by the LD-50 of the modulator, and theside-effects of the inhibitor at various concentrations, as applied tothe mass and overall health of the patient. Administration can beaccomplished via single or divided doses.

IX. Diagnostics and Kits

The present invention also provides methods for detection of p47ING3(either wildtype or mutant). For example, kits are provided that containp47ING3 specific reagents that specifically hybridize to p47ING3 nucleicacid, such as specific probes and primers, and p47ING3 specific reagentsthat specifically bind to the protein of choice, e.g., antibodies. Themethods, kits, and the assays described herein can be used foridentification of modulators of p47ING3, or for diagnosing patients withmutations in p47ING3.

Nucleic acid assays for the presence of p47ING3 DNA and RNA in a sampleinclude numerous techniques are known to those skilled in the art. Inparticular, p47ING3 specific reagents (e.g., p47ING3-specific primers ornucleic acid probes) can be used to distinguish between samples whichcontain p47ING3 nucleic acids and samples which contain p33ING1 orp33ING2 nucleic acids. Techniques such as Southern analysis, Northernanalysis, dot blots, RNase protection, high density oligonucleotidearrays, S1 analysis, amplification techniques such as PCR and LCR, andin situ hybridization can be used as assays. In in situ hybridization,for example, the target nucleic acid is liberated from its cellularsurroundings in such as to be available for hybridization within thecell while preserving the cellular morphology for subsequentinterpretation and analysis. The following articles provide an overviewof the art of in situ hybridization: Singer et al., Biotechniques4:230-250 (1986); Haase et al., Methods in Virology, vol. VII, pp.189-226 (1984); and Nucleic Acid Hybridization: A Practical Approach(Hames et al., eds. 1987).

In addition, p47ING3 protein can be detected with the variousimmunoassay techniques described above, e.g., ELISA, Western blotting,and the like. The test sample is typically compared to both a positivecontrol (e.g., a sample expressing recombinant p47ING3) and a negativecontrol. In particular, p47ING3, p33ING1 or p33ING2 specific polyclonaland monoclonal antibodies or specific polyclonal and monoclonalantibodies can be used as a diagnostic tool to distinguish betweensamples which contain p47ING3, p33ING1, or p33ING2 antigens.

The present invention also provides for kits for screening formodulators of p47ING3. Such kits can be prepared from readily availablematerials and reagents. For example, such kits can comprise any one ormore of the following materials: p47ING3, reaction tubes, andinstructions for testing p47ING3 activity. Preferably, the kit containsbiologically active p47ING3. A wide variety of kits and components canbe prepared according to the present invention, depending upon theintended user of the kit and the particular needs of the user.

EXAMPLES

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims.

Example I Cloning and Expression of p47ING3

p47ING3 homologous sequences were found in a random cDNA sequencedatabase consisting of short partial sequences known as expressedsequence tags (ESTs) submitted in GenBank. Using primers designed basedon these EST sequences and using RT-PCR and 5′- and 3′-RACE methods,p47ING3 coding region (SEQ ID NO:2) from human placenta cDNA (CLONTECH)was isolated and subcloned into a plasmid. The amino acid sequence ofp47ING3 (SEQ ID NO: 1) has about 34% amino acid identity with p33ING1(SEQ ID NO: 8 (p33ING1)) and p33ING2 (SEQ ID NO: 6 (p33ING2).

Example II Antibodies to p47ING3 Against Interior Peptide Sequence

Antibodies to p47ING3 were synthesized against the peptide ping-3 fromp47ING3 (SEQ ID NO:5: HTPVEKRKYNPTSHHTT). The peptide is amino acids141-157 of SEQ ID NO: 1. The peptide was purified by HPLC; peptide KLHconjugations were made; and rabbits were immunized by them. Antiserumwas purified using peptide affinity column and specificity of eachpolyclonal antibody was analyzed by ELISA.

p33ING1, p33ING2, and p47ING3 proteins were produced by Promega's TNTQuick Coupled Transcription/Translation System (Rabbit ReticulocyteLysate) from pcDNA3.1-ING1, ING2, and ING3 expression vectors.

Plasmids encoding p33ING1, p33ING2, and p47ING3 were separatelysubjected to an in vitro transcription/translation system to produce therespective proteins. The proteins were electrophoresed on SDS-PAGE andWestern blotted. The blot was incubated with anti-p47ING3 polyclonalantibodies and detection was performed using a horse radish peroxidaselabelled system from Amersham Pharmacia Biotech. As shown in FIG. 1,anti-p47ING3 polyclonal antibodies are reactive with recombinant p47ING3protein, but are not cross-reactive with recombinant p33ING1 protein orrecombinant p33ING2 protein. The p47ING3 protein migrates an a sizeappropriate for its predicted molecular weight of 47 kDa.

Example III Antibodies to p47ING3 Against N-terminal Sequence

Antibodies to p47ING3 were synthesized against the peptide Ping-3N fromp47ING3 (SEQ ID NO:9: MLYLEDYLEM; amino acids 1-10 of SEQ ID NO: 1). Thepeptide was purified by HPLC; peptide KLH conjugations were made; andrabbits were immunized by them. Antiserum was purified using peptideaffinity column and specificity of each polyclonal antibody was analyzedby ELISA and Western blot analysis.

p33ING1, p33ING2, and p47ING3 were produced by Promega's TNT QuickCoupled Transcription/Translation System (Rabbit Reticulocyte Lysate)from pcDNA3.1-ING1, ING2, and ING3 expression vectors.

Plasmids encoding p33ING1, p33ING2, and p47ING3 were separatelysubjected to an in vitro transcription/translation system to produce therespective proteins. The proteins were electrophoresed on SDS-PAGE withmolecular weight markers (Kaleidoscope Prestained Standards; Bio-Rad;161-0324) and Western blotted to a Immobilon-P membrane (Millipore,IPVH15150). The blot was incubated with anti-p47ING3 polyclonalantibodies (1:200 dilution) and detection was performed using asecondary antibody—goat anti-rabbit IgG HRP conjugate (Santa CruzBiotechnology, sc-2004) (1:2000 dilution). Detection was carried outusing ECL Western Blotting Detection Reagents (Amersham PharmaciaBiotech, RPN2106) and Hyperfilm ECL (Amersham Pharmacia Biotech,RPN2103K). The autoradiogram of the Western blot is depicted as FIG. 2.

As shown in FIG. 2, anti-p47ING3 polyclonal antibodies are reactive withrecombinant p47ING3 protein, but are not cross-reactive with recombinantp33ING1 protein or recombinant p33ING2 protein. The immunoreactive bandin the p47ING3 lane protein migrates an a size appropriate for thepredicted molecular weight of p47ING3 of 47 kDa.

Example IV Inhibition of Cell Proliferation

The colony formation assay was used to determine if p47ING3 inhibitscell growth of the RKO human colon carcinoma cell line which isavailable from the ATCC. A mammalian expression vector (with CMVpromoter, Neomycin resistant) containing p47ING3 in the senseorientation (pcDNA3.1-p47ING3) was constructed in the expression vectorpcDNA3.1 (Invitrogen). RKO cell lines were transfected with the parentvector pcDNA3.1 or with pcDNA3.1-p47ING3. The transfected cells wereselected with G418 to clone those cells with neomycin resistance. TheRKO (pcDNA3.1) and the RKO (pcDNA3.1-p47ING3) cell lines were subjectedto the colony formation assay was analyze the effect of p47ING3 oncellular proliferation. As shown in FIG. 3, RKO cells transfected withpcDNA3.1-p47ING3 formed less colonies compared to RKO cells transfectedwith pcDNA3.1. This result illustrates that p47ING3 can inhibit cellgrowth.

Example V Cell Cycle Assay of p47ING3 Transfected Cells

Cell-cycle stage analysis of cells transfected with an expression vectorencoding p47ING3 was performed using the method of Jiang and Hunter,supra. The method permits the analysis of cell-cycle profiles intransfected cells using a membrane-targeted green fluorescent protein(GFP).

RKO cells were plated in a 50 cm² dish at a density of 1×10⁴ cells/cm².Plasmid DNA mixtures that contained 0.15 picomoles of pEGFP-F Amp witheither 0.015 picomoles of pcDNA3.1 (Invitrogen) or 0.015 picomoles ofpcDNA3.1-p47ING3 were transfected using LipofectAMINE reagent (LifeTechnologies). Vector pEGFP-F Amp (ampicilin resistant) was constructedfrom vector from peGFP-F by replacing the kanamycin resistance gene withan ampicilin resistance gene. Vector pEGFP-F is available for Clontechand is kanamycin resistant.

After 3 hours of incubation, the medium was changed to fresh DMEM with10% FBS. After an additional 48 hour incubation, the cells wereharvested, fixed in 70% ethanol and then suspended in PBS containing 20μg/ml propidium iodide and 100 μg/ml RNaseA. The propidium iodide signalwas used as a measure for DNA content to determine cell-cycle profileson a FACScan flow cytometer (Becton-Dickinson). The cell cycle stage ofthe cell was analyzed after gating cells by GFP fluorescence usingFACscan. Cells with a green fluorescent signal at least 2 times strongerthan that in the negative cells are considered GFP-positive and cellswith a signal equal to or less than negatives cells are consideredGFP-negative. Those cells exhibiting a green fluorescent signal at least2 times stronger than that in the negative cells were consideredGFP-positive and cells with a signal equal to or less than negativescells were considered GFP-negative. The percentages of the cells in eachcell cycle phase ((G₀/G₁), S and (G₂/M)) were calculated by the ModFitprogram (Becton-Dickinson) (FIG. 4). The cell-cycle profiles ofGFP-positive and GFP-negative populations from the same dish can becompared. Typically, each DNA histogram contains data from at least10,000 cells. In this experiment, the RKO cells transfected withpcDNA3.1-p47ING3 have 13.4% more cells in the G₀/G₁ phase as compared toRKO cells transfected with pcDNA3.1 (FIG. 4). The percentage of RKO(pcDNA3.1) cells in the S and G₂/M phases is higher than RKO(pcDNA3.1-p47ING3) cells. This indicates that p47ING3 is able toincrease the number of cells in the G₀/G₁ phase. Therefore, it appearsthat p47ING3 is able to induce cell cycle arrest at G0/G1 phase anddecrease the number of RKO cells that are entering S phase (DNAsynthesis).

Example VI Soft Agar Assay for Identifying Compounds that Modulatep47ING3

Wildtype or mutant p47ING3 is expressed in host cells to screencompounds that modulate anchorage dependence of host cells expressingp47ING3. This is achieved by using the method disclosed in Garkavtsev etal. (1996), supra, herein incorporated by reference. NMuMG cells aretransfected with retrovirus produced from a vector containing p47ING3 insense or antisense orientation, or a vector lacking insert (control).The soft agar culture is comprised of two layers: an underlay (DMEM, 10%FCS, 0.6% agar) and an overlay (DMEM, 10% FCS, 0.3% agar), 5×10⁴ cellsare plated in soft agar in 10 cm plates are left at 37° C. for 6-7 weeksbefore being counted. The cells are incubated with a test compound for asuitable amount of time, e.g., for 0.5 to 48 hours, before countingcells. The amount of cells in the test sample is then compared tocontrol cells untreated with the compound.

All publications, patents, and patent applications cited herein arehereby incorporated by reference in their entirety for all purposes.

1. An isolated monoclonal antibody that selectively binds to a p47ING3polypeptide of SEQ ID NO: 1, wherein the antibody binds to an amino acidsequence selected from the group consisting of SEQ ID NO:5 and SEQ IDNO:9.
 2. The antibody of claim 1, wherein the antibody binds to theamino acid sequence of SEQ ID NO:5.
 3. The antibody of claim 1, whereinthe antibody binds to the amino acid sequence of SEQ ID NO:9.
 4. Anisolated antibody that selectively binds to a p47ING3 polypeptide of SEQID NO: 1, wherein the antibody binds to the amino acid sequence of SEQID NO:9.
 5. A method of detecting the presence or absence of the p47ING3polypeptide SEQ ID NO:1 in a tumorigenic mammalian tissue using theantibody of claim 1 or 4, the method comprising the steps of: (i)isolating a tumorigenic sample; (ii) contacting the tumorigenic samplewith the p47ING3 antibody of claim 1 or 4; and (iii) detecting the levelof p47ING3 antibody that selectively associates with the tumorigenicsample, thereby detecting the presence or absence of the p47ING3polypeptide in tumorigenic mammalian tissue.